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dossier to the European Chemicals Agency (ECHA) containing 
an extensive list of data on the intrinsic properties of a substance, 
ranging from chemical characterization and physicochemical prop-
erties to toxicological and ecotoxicological data, with increasing 
demands depending on the tonnage band of the quantity of the sub-
stance placed on the market. In addition, registrants should col-
lect information on use and exposure to perform a chemical safe-
ty assessment (CSA) based on the toxicity profile of the substance. 
The minimum data requirements are described in Annexes VI-X 
of the regulation. For toxicological testing, the standard require-
1  Introduction
1.1  Background
In 2006, the REACH Regulation (Registration, Evaluation, 
Authorisation and Restriction of Chemicals, Regulation EC 
1907/2006) was adopted in the EU, starting a new era of chemi-
cal assessment and asking for an unprecedented level of effort in 
collecting toxicological data on chemicals that were already on the 
market (Hartung, 2010a). Under REACH, importers and manufac-
turers of chemical substances are obliged to submit a registration 
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and workshop organized by the German Federal Institute for Risk 
Assessment (BfR, 2018a,b). In many cases, RAx justifications by 
the registrants lacked important information, specifically with re-
gard to explaining the influence of structural differences between 
source(s) and target(s), and justification of the inclusion/exclusion 
of group members. However, when performed correctly, RAx is 
probably the most direct approach for adapting standard informa-
tion requirements. 
Under Title VI, Chapter 1 (Dossier Evaluation) of the REACH 
Regulation, ECHA must evaluate the submitted dossiers for com-
pliance with regulatory requirements. To that end, ECHA has im-
plemented a system to manually check all dossiers containing 
waiving of standard information, as is the case when RAx is in-
cluded in a REACH registration dossier. In this context, rejecting 
RAx due to inadequate justification has been shown to be one of the 
main reasons for requesting further (i.e., always in vivo) data from 
the registrants. Notably, a RAx justification will be rejected when 
ECHA considers the RAx hypothesis by the registrants implausi-
ble but also if the documentation provided is inadequate to allow a 
reliable assessment of its soundness. Given ECHA’s announcement 
to substantially increase their dossier evaluation activities, starting 
already in 20191, it is clear that adequately documenting valid RAx 
hypotheses in a scientifically sound way is a key issue when trying 
to avoid unnecessary animal testing under REACH.
Regarding RAx, ECHA issued a dedicated document describing 
the Read-Across Assessment Framework (RAAF) in 2015, which 
was updated in 2017 to include multi-constituent substances and 
substances of unknown or variable composition, complex reac-
tion products and biological materials (UVCB) (ECHA, 2017b,c). 
Originally, these publications were intended only to define the 
rules applied by ECHA when assessing the RAx strategies. Like 
any framework, the RAAF document provides high-level infor-
mation on the scope and the key elements a valid RAx justifica-
tion should contain but provides no detailed guidance on how a 
RAx justification should be prepared. It also lacks practical ex-
amples of accepted or rejected RAx justifications. However, the 
RAAF document is very useful, as it describes the basic princi-
ples of RAx, which should be supported by both strong chemical 
and biological similarity, and a scoring system for rating the ac-
ceptability of the RAx strategy. Notably, the RAAF was published 
late in the REACH process, i.e., when most of the REACH reg-
istration dossiers were already submitted or at an advanced stage 
of preparation. Being published in 2015, the RAAF was available 
only to REACH phase-in registrants submitting dossiers for the fi-
nal deadline, May 30, 2018, which included all substances market-
ed in the tonnage band above 1 t/y. 
As far back as 2012, the European Centre for Ecotoxicology 
and Toxicology of Chemicals (ECETOC) published a technical re-
port on the category approach, RAx and QSAR (ECETOC, 2012) 
that represents an introduction to the topic but provides only mi-
nor guidance on how to prepare and submit a RAx justification 
document to the regulatory authorities. Many of the recommenda-
tions proposed in the ECETOC document were later incorporated 
in an OECD guidance document for grouping that was published 
ments ask for in vivo or in vitro tests according to Regulation EC 
440/2008, though tests performed according to OECD (Organi-
sation for Economic Co-operation and Development) guidelines 
are generally accepted. Rovida and Hartung (2009) predicted that 
full compliance with the REACH Regulation would have required 
an enormous number of animals. This did not happen because 
fewer chemicals than expected were registered and because 
REACH permits waiving of the standard studies by applying a 
suitable adaptation to the standard required endpoint information. 
This opportunity is detailed in Annex XI of the REACH regula-
tion, which also defines grouping of substances and the read-across 
(RAx) approach as: “Substances whose physicochemical, toxico-
logical and ecotoxicological properties are likely to be similar or 
follow a regular pattern as a result of structural similarity may be 
considered as a group or ‘category’ of substances. Application of 
the group concept requires that physicochemical properties, hu-
man health effects, and environmental effects or environmental 
fate may be predicted from data for reference substance(s) within 
the group by interpolation to other substances in the group (read-
across approach). This avoids the need to test every substance for 
every endpoint.”
Generally speaking, RAx is a technique used to predict end-
point information for one chemical by using data from the same 
endpoint from (an)other chemical(s) that is considered to be sim-
ilar in some way. If data are read across from one or only a few 
source substances, this is often called an “analogue approach”. In 
contrast, grouping refers to the definition of a set of substances 
combined in a category, where their known toxicological proper-
ties follow a specific trend that can be used to infer the properties 
of the chemicals belonging to it. The precise border of distinction 
is not defined, because one-to-one comparison is often supported 
by evidence gained with other, similar chemicals. For this reason, 
RAx, as used in this report, represents any approach where a da-
ta gap is filled using existing information obtained for other sub-
stances (Patlewicz et al., 2014).
REACH Annex XI describes also other approaches to waive 
tests, including quantitative structure activity relationships 
(QSARs), weight-of-evidence (WoE), and in vitro testing. Among 
the non-testing approaches, no distinct edge between RAx, WoE 
or QSAR can be defined, and thus these three techniques may be 
combined. 
According to the latest ECHA report (ECHA, 2017a) on the 
general use of alternative methods for REACH purposes, RAx has 
been extensively used in REACH registration dossiers, in particu-
lar for human health data endpoints. Indeed, alternative strategies 
have been used in about 34% of the dossiers for lower tier toxi-
cological endpoints, e.g., local and acute endpoints for substanc-
es up to 100 t/y, whereas alternative strategies were employed 
in nearly 84% of the dossiers for substances above 100 t/y in the 
assessment of higher tier endpoints, e.g., repeated dose toxicity, 
and reproductive and developmental toxicity. The evaluation of 
these dossiers by ECHA found overall poor quality of the infor-
mation provided, leading to low acceptance rates, as outlined by 
Ball et al. (2016) and ECHA. This was corroborated by a report 
1 https://newsletter.echa.europa.eu/home/-/newsletter/entry/reach-compliance-an-agency-priority-for-2019
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in 2014 (OECD, 2014) and updated in 2017 (OECD, 2017a). The 
latter describes the difference(s) between the analogue approach, 
where the comparison between source and target is mostly one-
to-one and there is no difference in activity, and the category ap-
proach, where the toxicological assessment is performed on a 
group of chemicals for which the specific endpoint has a regular 
pattern or trend within the category. The innovative aspect was to 
provide some more guidance on how to go about crafting the RAx 
justification and start the discussion about where in vitro testing 
and adverse outcome pathways (AOPs) could play a role.
Acknowledging the needs for further guidance and agree-
ment on how to build and apply a good RAx strategy, some ini-
tiatives were undertaken in the EU and in the US (Fig. 1). In 
2016, CAAT-Europe, Cefic-LRI and EU-ToxRisk hosted a work-
shop (Maertens et al., 2016) to initiate a discussion on Good Read 
Across Practice (GRAP). This was followed by a similar initia-
tive in the US2 with the collaboration of the US Food and Drug 
Administration’s Center for Food Safety and Applied Nutrition 
(FDA-CFSAN) accompanied by a satellite meeting at the Annu-
al Meeting of the Society of Toxicology (SOT) in 2018 relating to 
the specific topic of regulatory acceptance of RAx (Chesnut et al., 
2018). The intent was to summarize the state-of-the-art and pro-
vide examples and strategies for how to provide RAx justification 
based on the experience of industry registrants at the time. 
A complementary document (Zhu et al., 2016) described the 
possible contribution of biological information to structure-based 
RAx. These concepts were also discussed at a workshop organized 
by ECHA in 2016 (ECHA, 2016, 2017d), arriving at the conclu-
sion that new in vitro tests can be applied to justify RAx approach-
es. For the first time, the term “new approach methodologies” 
(NAMs) was introduced and taken “in a broad context to include 
in silico approaches, in chemico and in vitro assays, as well as 
the inclusion of information from the exposure of chemicals in the 
context of hazard assessment”. NAMs also embrace other infor-
mation on toxicodynamics (e.g., high-throughput screening and 
high content-methods) and toxicokinetics with the aim of improv-
ing the understanding of toxic effects (van Vliet et al., 2014). 
Currently, the EU-ToxRisk project, which is an Integrated Eu-
ropean “Flagship” Programme driving mechanism-based toxicity 
testing and risk assessment for the 21st century (Daneshian et al., 
2 http://caat.jhsph.edu/programs/workshops/readacross.html 
Fig. 1: Timeline of the development of RAx application for risk assessment
Schematic representation illustrating the key dates and documents for the development of the RAx application for regulatory purposes  
in Europe and within the EU-ToxRisk Project. Reference documents as mentioned in the text: 1 http://data.europa.eu/eli/reg/2006/1907/oj;  
2 http://data.europa.eu/eli/reg/2008/440/oj; 3  https://bit.ly/2IqOBJB; 4 https://echa.europa.eu/documents/10162/13628/raaf_en.pdf;  
5 Maertens et al., 2016; 6 ECHA, 2017b; 7 Ball et al., 2016; 8  https://bit.ly/3jVbYJ9; 9 https://bit.ly/3dl4Ing. The EU-ToxRisk final deliverable 
will represent an advisory document, complimentary to the already published ECHA reporting template for grouping and read-across 
(ECHA RAAF), facing the issue of regulatory acceptance from the point of view of the registrants of NAM-supported read-across dossiers.
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in silico methods, are now included and promoted in many regu-
lations across countries and sectors. As an example, the situation 
in some countries is considered here (Fig. 2), without the claim of 
providing an extensive analysis.
In the US, there is minimal application of RAx for official reg-
ulatory dossiers, and there are no formal protocols, procedures or 
guidance documents on its use. To date, the most widely known 
use cases in the US are those within the US Environmental Pro-
tection Agency (EPA) that already have been captured in the cur-
rent OECD guidance (OECD, 2017), such as experiences under 
the Pre-Manufacture Notice (PMN) process or High Production 
Volume (HPV) program (van Leeuwen et al., 2009) as well as 
the chemical categories used to review new chemicals under the 
Toxic Substances Control Act (TSCA)3. The US EPA’s Office of 
Pollution Prevention and Toxics (OPPT), whose experience with 
RAx approaches is relatively mature, has developed the Analogue 
Identification Methodology4 (AIM) and the Chemical Assessment 
Clustering Engine (ChemACE)5, specifically designed to assist, 
review and prioritize large inventories of chemicals and to facili-
tate RAx and data gap-filling for untested substances. The activity 
of OPPT started in 2010, with the publication of the New Chemi-
cal Categories document (OPPT, 2010) that was intended to pro-
vide an effective tool for EPA reviewers to benefit from the accu-
mulated data and past decisions as precedents. This document col-
lects the different substances grouped by main chemical functional 
groups that are supposed to result in a specific physicochemical 
or toxicological property of the molecule. The Interagency Co-
ordinating Committee on the Validation of Alternative Methods 
(ICCVAM) has shown continued interest in the potential of RAx 
to waive new tests on vertebrate animals. In 2016, ICCVAM 
broadcast a dedicated webinar6 and established a working group 
focused on RAx, which was assigned the task of summarizing best 
practices for the application and implementation of RAx in the dif-
ferent regulatory settings of interest. A recent publication by the 
ICCVAM RAx working group summarized current needs and op-
portunities across US agencies, including decision contexts, de-
sired activities, and any available guidance, and provided a list of 
freely available RAx tools (Patlewicz et al., 2019). This paper also 
detailed two specific case studies to illustrate how RAx is applied 
in practice: the EPA evaluation of n-heptanal under the Superfund 
program and a toxicological risk assessment for a medical device 
at the US FDA.
In Canada, Health Canada and Environment and Climate 
Change Canada’s risk assessment programs have continued to in-
crease the use of RAx in risk assessments throughout the evolution 
of the three phases of the Chemicals Management Plan (CMP). 
RAx was introduced as a key approach to support risk assessment 
during Phase 2 of the CMP (Substance Groupings Initiative 2011-
2015)7, where chemicals began to be assessed as groups based on 
structural, functional or mechanistic similarities, and is now rou-
2016), aims to move away from observational toxicology based 
on animal models and progress towards a toxicological assess-
ment based on in vitro test responses using human cells together 
with a better mechanistic understanding of chemical adverse ef-
fects. The research is focused on two in vivo endpoints: repeat-
ed dose systemic toxicity (e.g., Hiemstra et al., 2019; Albrecht et 
al., 2019; Delp et al., 2019,) and developmental and reproductive 
toxicity (e.g., Rempel et al., 2015; Nyffeler et al., 2017; Delp et 
al., 2018). One of the first applications of the in EU-ToxRisk in 
vitro and in silico test batteries is applying the RAx hypothesis 
(Graepel et al., 2019; Escher et al., 2019). With this goal, the proj-
ect has developed ad hoc case studies to be reviewed by regulators 
from ECHA and EU Member States with the aim of further im-
proving the understanding of what constitutes an acceptable RAx 
justification and how this justification can be supported and im-
proved using NAM data. The integrated results were submitted to 
regulators from ECHA and EU Member State competent authori-
ties as mock dossiers and discussed in a workshop with stakehold-
ers from academia, industry and authorities in May 2019 (manu-
script in preparation).
The ongoing general discussion on RAx has confirmed the com-
plexity of the approach and the need to establish suitable rules 
for its objective application, leading to a broader regulatory ac-
ceptance of RAx for the risk assessment of chemicals. With this 
goal, a group of stakeholders, coming from many different areas, 
expertise and organizations, including regulatory, validation and 
government bodies, was convened in Ranco (Varese, Italy) on Ju-
ly 16-18, 2018. During that workshop, sponsored and co-orga-
nized by CAAT-Europe, the EU-ToxRisk project and the Doeren-
kamp-Zbinden Foundation (DZF), it was decided to prepare an 
extensive document to present the state-of-the-art of RAx for reg-
ulatory purposes with the addition of further comments to foster 
its applicability for regulatory purposes. The present report, which 
benefits also from the contribution of experts who did not partic-
ipate in that meeting, has the ambitious goal to describe the basis 
for immediate improvement of RAx acceptance as well as to de-
fine the strategy for future development in a contribution that may 
serve as an educational text both for those who are facing the argu-
ment for the first time and those who want to deepen it. The con-
cepts and ideas presented here come from the individual partici-
pants and do not necessarily reflect the views and opinions of the 
organizations they represent. The debates were based on scientific 
discussions among the participants, without a necessarily unani-
mous final agreement on all issues.        
1.2  The international dimension of RAx 
The EU was the first group of countries to accept RAx as a tool to 
address information requirements in lieu of standard testing, but 
for proper implementation of the new approach, greater interna-
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ed by the case study for a group of substituted phenols (Webster 
et al., 2019). 
Other countries have adopted legislations very similar to 
REACH, but not equally advanced in the promotion of alternative 
methods. For example, in South Korea the structure of K-REACH 
resembles that of the EU approach but lacks all reference to the 
possibility to adapt standard information (Ha et al., 2016). This 
means that the RAx approach is acceptable but not applied. The 
first deadline for registering substances in the tonnage band above 
1000 t/y will be in 2021, and it is now too early for any analysis of 
this topic.
In Australia, the Industrial Chemicals (Notification and Assess-
ment) Act 1989 will be replaced on 1 July 2020 by the Industrial 
Chemicals Act 201910. This act contains no details on the toxico-
logical tests that will be in dedicated guidelines still under con-
struction at the time of writing. However, this new law includes 
the ban on animal tests on cosmetic ingredients.
A candidate country for accession to the EU, Turkey’s program 
includes the harmonization of its legislation. KKDIK, the Turk-
ish version of REACH, is very similar to the EU’s REACH reg-
ulation. However, since KKDIK came into effect only in 2017, 
with pre-registration and registration deadlines in 2020 and 2023, 
tinely used in the risk assessment of new and existing substances 
in Phase 3 (2016-2020). The Government of Canada gained ex-
perience in using RAx by contributing to the development of the 
OECD guidance on the grouping of chemicals and subsequent up-
dates (OECD, 2014, 2017a) and through expert consultation from 
the CMP Science Committee on best practices for deriving a suf-
ficient rationale to support risk assessment decisions within the 
context of the CMP8. As the CMP in Canada continues to advance 
and modernize, RAx remains a critical tool contributing to the 
WoE evaluation9 and reducing uncertainty in an assessment, as 
well as permitting the assessment of substances that would other-
wise have insufficient information. It can also provide verification 
or validation of other data to fill endpoint-specific data gaps and 
support the identification of needs for further testing. The RAx 
tools and approaches that have been developed and implemented 
under the CMP are evolving to facilitate the integration of emerg-
ing data sources and NAM data for the formation of chemical cat-
egories to support the identification of groups of chemicals as risk 
assessment priorities in moving forward. Furthermore, there is 
on-going development of computational approaches for analogue 
selection for RAx to advance risk assessment through integrated 
approaches to testing and assessment (IATA) such as that illustrat-
Fig. 2: Overview of the current legislations covering RAx regulatory applications worldwide 
ANVISA, Agência Nacional de Vigilância Sanitária (Brazilian National Health Surveillance Agency); CMP, Chemicals Management Plan; 
CSCL, Chemical Substances of Control Law; HESS, Hazard Evaluation Support System; HPV, High Production Volume; OPPT,  
Office of Pollution Prevention and Toxics; PMN, Pre-Manufacture Notice; REACH, Registration, Evaluation, Authorisation and Restriction  
of Chemicals; TSCA, Toxic Substances Control Act. This list is not intended to be complete.
8 https://www.canada.ca/en/health-canada/services/chemical-substances/chemicals-management-plan/science-committee/meeting-records-reports/committee-report- 
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ing and RAx strategies for a cost-effective solution. The approach 
is to integrate innovations in (i) in vitro testing, (ii) high-throughput 
genomics, and (iii) integrative data analyses and visualization into 
a transparent workflow for RAx assessment. This approach offers 
interesting perspectives; however, it remains to be seen whether the 
results produced will ultimately affect the formation of more reli-
able categories that are acceptable from a regulatory point of view.
Another industrial association that is very active in this field is 
the International Fragrance Association (IFRA). Similar to petro-
leum products, many fragrances are also UVCBs, often with un-
clear structures and embracing many different chemical class-
es. Fragrances are common ingredients of cosmetic products, and 
their precise toxicological characterization is of the utmost impor-
tance. In the case of fragrances, and for the whole cosmetic sec-
tor in general, the opportunity of performing risk assessment us-
ing the RAx approach is highly appealing (Api et al., 2015). In 
fact, more than other industry branches, the cosmetics industry 
needs very accurate animal-free prediction methods for possible 
adverse health effects in humans due to the prohibition of testing 
in vertebrates by the EU Cosmetics Regulation (EC) 1223/2009. To 
demonstrate how this topic is of outstanding importance, the Euro-
pean Union’s Scientific Committee on Consumer Safety (SCCS) 
has published a call to hire RAx experts, acknowledging that as-
sessment of cosmetic ingredients is increasingly based on this ap-
proach.
RAx is also applied in the evaluation of chemical constituents 
within dietary supplements (Cohen et al., 2018). For example, the 
US FDA has used computational modelling of the 25 most preva-
lent substances in Kratom, a material of plant origin, to compare 
structural similarities with opioid analgesics13. They then used this 
information, together with previously available experimental data, 
to determine the substances’ biological targets. Also in this area, 
botanical safety can be evaluated using RAx in combination with 
the threshold of toxicological concern (TTC), which is the estimat-
ed exposure level that is considered of negligible harm (Little et 
al., 2017). 
An emerging field of RAx application is the grouping of nano-
materials. Many different nanomaterials are used in various sectors, 
ranging from cosmetics to paints to drugs. Specific biological ac-
tivities of nanomaterials, which may be determined by their shape, 
size and/or surface properties, might not be fully captured by tradi-
tional toxicological methods, and testing all of these materials with 
in vivo methods seems impossible (Hartung, 2010b; Hartung and 
Sabbioni, 2011). A major challenge of applying grouping and read-
across to nanomaterials is the identification of those material prop-
erties that are critical for adverse outcomes of nanomaterial expo-
sure (Oomen et al., 2015; Burden et al., 2017). Current concepts 
for the grouping of nanomaterials for human health risk assess-
ment (e.g., Landsiedel et al., 2017) consider composition, solubili-
ty, morphology and/or surface reactivity. These concepts have been 
developed further within the EU GRACIOUS project14. Mech et al. 
respectively, it is not yet known to what extent adaptation to stan-
dard information requirements will be applied.
The Japanese Hazard Evaluation Support System (HESS) data-
base and platform11, which was started in 2012 and has been updat-
ed regularly, is promising with respect to RAx application. HESS 
supports the evaluation of repeated dose toxicity by category ap-
proach and is linked to two databases. The first is a toxicity knowl-
edge database, which contains information on repeated-dose toxic-
ity and toxicity mechanisms. The second is a metabolism knowl-
edge database containing rat metabolism maps and information 
on absorption, distribution, metabolism and excretion (ADME) in 
rats and humans. HESS allows chemicals to be categorized on the 
basis of structural, physicochemical and mechanistic similarities 
and supports the prediction of repeated-dose toxicity for untested 
chemicals by means of the category approach. Regarding the legis-
lative framework, chemical substances are regulated by the Chem-
ical Substances of Control Law (CSCL) that may accept a RAx 
approach for hazard assessment on a case-by-case basis upon the 
formal approval of a scientific committee. However, so far, the ap-
plication of RAx for regulatory purposes has been limited.
Regarding Brazil, the Guide for Safety Assessment of Cosmetic 
Products published by the Brazilian National Health Surveillance 
Agency (ANVISA – Agência Nacional de Vigilância Sanitária) 
suggests the use of in silico models for selection of raw materi-
als in order to avoid the use of unsafe chemicals. It also states that 
such results must be carefully used and do not fully replace vali-
dated in vitro or in vivo models. For drugs and biological products, 
impurity mutagenesis must be evaluated by two in silico methods 
(expert rule-based and statistics based). Read-across is not fully 
acceptable for general toxicity. The Brazilian Center for Valida-
tion of Alternative Methods (BraCVAM) encourages the use of the 
RAx concept, at least at the beginning of a study, as part of the in-
tegrated testing strategy (ITS).          
1.3  Applications 
Given its inherent potential for huge economic savings and sci-
entific innovation, industry is, in general, open to the opportuni-
ty of RAx, provided that there are clear rules for its applicabili-
ty and guarantees for regulatory acceptance. Some key examples 
are provided here.
The petrochemical industry represented by CONCAWE, a di-
vision of the European Petroleum Refiners Association, is study-
ing the environmental health and safety of petroleum deriva-
tives. The problem of petroleum products is that they are complex 
UVCBs with highly variable compositions. Grouping is generally 
performed through general similarities of analytical characteriza-
tion and physicochemical characteristics, which are not sufficient 
in many cases to justify RAx hypotheses. For this reason, CON-
CAWE has sponsored a new project, called Cat-App12, with the fi-
nal goal of addressing the specific challenge posed by UVCBs such 
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both legislations ask for ISO test methods. In theory, in vitro tests 
and RAx are not prohibited, but the probability that regulators will 
request confirmation with in vivo tests usually leads applicants to 
immediately perform in vivo methods to avoid the risk of dupli-
cate testing (Rovida, 2010), which increases costs and causes de-
lays to marketing (Kerecman Myers et al., 2017). 
Drug safety assessment shares a very similar situation. The Eu-
ropean Medicines Agency (EMA), FDA and other governmental 
institutions with responsibilities in the approval of new drugs de-
clare a willingness to consider any new approach if its scientific va-
lidity is demonstrated, but in the end, all substances must undergo 
extensive in vivo tests for acceptance. At present, RAx is neverthe-
less applied and accepted for the evaluation of drug impurities that 
cannot be isolated and characterized15. In this sense, RAx is for-
mally accepted in the risk assessment of non-tested contaminants 
(EMA, 2014). Pharmaceutical companies extensively apply in sili-
co methods during drug discovery and development to detect drug 
candidates with potential safety concerns, which are then removed 
from the development pipeline to save costs and minimize risks.
The EU Plant Protection Products Regulation (Regulation (EU) 
1107/2009), while acknowledging the general principle of avoid-
ing unnecessary animal testing, does not make specific reference 
to RAx. Article 5 of Regulation (EU) 283/2013 (detailing the data 
requirements for pesticide active substances) states that “tests on 
vertebrate animals shall be undertaken only where no other val-
idated methods are available. Alternative methods to be consid-
ered shall include in vitro methods and in silico methods,” and 
arguably RAx could be considered an in silico method, in partic-
ular when supported by in silico tools such as the OECD QSAR 
Toolbox16. However, for the assessment of pesticide active ingre-
(2018) reviewed the regulatory acceptance of RAx applied to nano-
materials and pointed out that specific guidance for implementing 
grouping and RAx of nanomaterials still needs to be developed. 
There is, however, consensus (e.g., OECD, 2016a) that for nanoma-
terials, particularly nanoforms of the same chemical composition, 
grouping and RAx can help to reduce testing while still obtaining 
sufficient information to assess their risks. Under REACH, ECHA 
has issued a guidance appendix relevant for nanomaterials (ECHA, 
2017e). Similarly, this has been highlighted as an option in the EF-
SA guidance on the application of nanoscience and nanotechnolo-
gies in the food and feed chain (EFSA, 2018a). Several case studies 
on nanomaterial RAx are available for specific endpoints or expo-
sure routes (Arts et al., 2016; Aschberger et al., 2019).
Another sector where the potential of the RAx approach can be 
important is the assessment of polymers, whose toxicological as-
sessment is seldom performed. In addition to that, the question 
about the impact of microplastics in the environment is only start-
ing to be considered from a toxicological point of view. The only 
exceptions are in the application of polymers as food contact ma-
terials. In general, risk assessment of food contact materials is per-
formed only on migrating substances. 
The field of medical devices is definitely more complex. In 
the EU, medical devices are in the scope of the new EU Regula-
tion 2017/745, which is still in the transition period until May 26, 
2020. When fully in force, this regulation will require far more de-
manding tests to approve new products, in particular those with 
chronic exposure. Since it is new, there is time to improve the use 
of RAx, which is completely absent from the authorization dos-
siers of existing products. Toxicological assessment of medical 
devices in the US is very similar to that proposed in the EU, as 
Fig. 3: Industry sectors affected by  
the application of the RAx approach for 
risk assessment 
Affected products range from industrial 
chemicals, cosmetics, medical drugs 
and pesticides, to petroleum products, 
nanomaterials, and polymers. Tiles are 
outlined in shades representing maturity  
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isomer of the target compound or a salt with a different counte-
rion or a substance sharing the same scaffold with minor differ-
ences in molecular weight. In other cases, the selection of source 
compounds is not trivial and requires the support of reliable com-
putational tools that may assist in the identification of the prop-
er chemical or group of chemicals. For this, the structure of the 
target substance should be transferred into a notation for molec-
ular descriptions, for instance Simplified Molecular-Input Line- 
Entry System (SMILES) strings or the IUPAC International Chem-
ical Identifier (InChI) keys, which are typically used as input in-
to software for the calculation of molecular descriptors and phys-
icochemical properties as well as molecular modelling (Heller et 
al., 2015). Some in silico methodology, e.g., docking simulations 
or molecular dynamic simulations, may require three-dimensional 
structural information (Luechtefeld and Hartung, 2017). The com-
putational tool most frequently applied in the area of RAx is the 
OECD QSAR Toolbox16, which represents a good starting point 
for the identification of possible source substances. The QSAR 
Toolbox16 profiles molecules according to their chemical structure 
and corresponding possible reactivity in order to define criteria for 
category formation and provides the basis to explain the presence/
absence of hazards or other properties.
After collecting candidates for source substances, the next step 
is the collection of all available information to fill the data gap 
and demonstrate similarity. A possible source compound is use-
less if there are no data or the available data are not accessible for 
any reason, such as the study report is proprietary or simply not 
available. Furthermore, existing information needs to be catego-
rized and, in particular, all data should be analyzed to understand 
the mechanistic knowledge that they may bring along in order to 
identify biological pathways responsible for the outcome of an ad-
verse effect that can be combined to substantiate the mechanism of 
action of target and source substances. If the mechanism behind an 
endpoint is unknown, chemical similarity and computational tools 
may still assist the hypothesis, but in this case, the prediction will 
be associated with a higher degree of uncertainty. 
After the identification of possible source substances, and col-
lection and categorization of the existing information, the next 
step is the formulation of a possible RAx hypothesis. Its confirma-
tion may need the identification of a subset of assays and experi-
mental tests to confirm the overlap of biological behavior through 
the demonstration that relevant key events are fully shared or 
that a regular trend exists (Zhu et al., 2016). In fact, evaluation 
of chemical similarity with Tanimoto metrics or other systems is 
useful but often not sufficient to demonstrate that the target and 
the source share similar properties for the endpoint under consid-
eration (Mellor et al., 2019). For both regulatory acceptance and 
scientific reasons, it is preferable to broaden the perspective to in-
clude biological similarities and ensure that all possible source 
substances are taken into proper consideration. 
The starting point of a strong similarity justification is the defi-
nition and characterization of all relevant physicochemical prop-
erties. This goal is achieved with the aid of available experimental 
dients, RAx is practically never used, though it is increasingly ap-
plied for pesticide impurities, metabolites and degradation prod-
ucts. RAx is also usually considered in the preliminary assessment 
during the gathering and organization of existing information 
(SAPEA, 2018). Only in the case of dietary assessment of pesti-
cide metabolites is RAx formally used and accepted, in particular 
for the evaluation of genotoxicity (EFSA, 2016). 
In contrast, Annex IV of the EU Biocidal Products Regulation 
(Regulation (EU) 528/2012) allows for the adaptation of stan-
dard information requirements in the same way as Annex XI of the 
REACH Regulation, and therefore analogue/grouping approaches 
are frequently employed. As an example, RAx was used to assess 
the similarity of 5-chloro-2-(4-chlorophenoxy)phenol (DCCP), a 
biocide approved for human hygiene, disinfection, food and ani-
mal feeds, to Triclosan, based on similar toxicokinetics measured 
in hamsters17.
Recently, ECHA and EFSA jointly prepared new guidance for 
the identification of endocrine disruptor properties of pesticides 
and biocides, in which a RAx opportunity is explicitly mentioned 
(ECHA/EFSA, 2018). 
In conclusion, there are plenty of opportunities for the use of 
RAx in the different industrial sectors, but they remain substan-
tially underexploited, even though the hope is for a more extensive 
application in the future (Fig. 3).      
2  Confidence building
2.1  Chemical and biological starting points for  
similarity assessment 
Though this paper is not intended to review all scientific possi-
bilities for RAx justification, it is important to provide the basic 
principles for the applicability of this approach to facilitate the 
discussion on validation and acceptance. 
A RAx hypothesis should start from a proper definition of the tar-
get substance(s) by providing the correct molecular structure and 
purity. In the case of multi-constituent substances, each component 
should be defined both with respect to its molecular structure and 
relative content in the target substance or, in general, the composi-
tion should be described as much as possible. Ideally, full spectrom-
etry characterization with mass spectrometry (MS) spectra, nuclear 
magnetic resonance (NMR) spectra of both hydrogen and carbon, if 
necessary, an infrared (IR) spectrum, and any other techniques that 
can be useful for the proper definition of the compound should be 
provided for each substance. This process should be aimed at the 
characterization of the whole sample rather than a mere definition 
of the main component. For this aim, the ECHA guidance for sub-
stance identification can be very helpful (ECHA, 2017f).
Once the characterization of the target substance is clear, the 
next step is the identification of one or more possible source sub-
stance(s). In many cases, the first approach is based on expert 
judgment derived from observation of the chemical structure. In 
comparatively easy scenarios, the source compound is a stereo-
17 http://dissemination.echa.europa.eu/Biocides/ActiveSubstances/1232-01/1232-01_Assessment_Report.pdf 
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tains information on more than 600,000 chemicals from over 200 
QSAR models19. Where models are used, they should be run also 
for category members for which experimental data exist. In this 
way, the applicability of the QSAR/QSPR model(s) to the specific 
set of chemicals under examination can be demonstrated. Where 
available, study results should be compared with the output of the 
computational approach as a reference to assess the accuracy of the 
prediction and claim better reliability for the output when applied 
to fill a data gap. Another computational tool developed specifical-
ly for RAx purposes is EPA’s Generalized Read Across (GenRA) 
add-in within the CompTox Chemicals Dashboard18, which uses a 
similarity-weighted activity algorithm to compute a RAx predic-
tion using both chemical (structural fingerprint) and biological (in 
vitro HTS data from the Tox21 program) descriptors.
Given that potential selection bias is one of the major issues 
with respect to the reliability of the RAx approach, it is essential 
to document selection and deselection as well as chemical and bi-
ological characterization of the source chemicals that have been 
performed according to a clear rationale and in an unbiased way. 
Whatever the amount and quality of existing information, there 
will always be some uncertainties that need to be characterized, 
quantified and accepted. Computational methods may be very use-
ful in providing variance and correlation among features. Uncer-
tainty should be defined for each piece of information and in case 
of discordant results for the same substance, a conclusion should 
be drawn carefully by weighing all available information and rele-
vant differences in the experimental protocol of the studies. Miss-
ing data and the lack of mechanistic coverage should be overcome 
with new ad hoc experimental studies.
2.2  New approach methodologies (NAMs) 
and adverse outcome pathways (AOPs)
As already mentioned, NAMs represent a good opportunity to 
support the RAx hypothesis by providing data to confirm wheth-
er a group of substances shares the same biological mechanism 
or if they show a specific trend within the category (Fig. 4). In the 
latter case, NAMs can help in the identification of the most rep-
resentative compounds for further testing and may also contrib-
ute to the definition of the boundaries for the group. In this sense, 
NAMs should constitute new experimental tests/predictions that 
are performed with the specific goal of demonstrating the RAx 
hypothesis. The strength of NAMs in RAx is that all members of 
the category are tested simultaneously with the same test meth-
od, and the results are assessed as a category, demonstrating sim-
ilarities and dissimilarities or providing clues to link the chemi-
cal structure to the biological activity. 
A plethora of in vitro and in silico techniques are now available 
and can assist in the purpose of demonstrating similarities within a 
category. Listing all the opportunities is out of the scope of this pa-
per, and more details are available elsewhere (e.g., Berggren et al., 
2015). NAMs are often organized to model a key event (KE) of 
an AOP, the principle of which is to describe a sequential chain of 
causally linked events at different levels of biological organization 
information or reliable in silico predictions for both the source and 
the target substance(s). The full set depends on the specific sub-
stance and the in vivo endpoint under investigation, but should in-
clude as a minimum:
– Water solubility;
– Melting and boiling point;
– Octanol/water partitioning (Ko/w);
– Volatility, e.g., as vapor pressure or Henry’s law constant;
– Particle size for powders;
– Stability (e.g., in air, aqueous solution, pH, light). 
Other properties should be considered based on the molecu-
lar structure and the endpoint in question. For endpoints such as 
(DNA-reactive) genotoxicity or skin sensitization parameters, es-
timating the electrophilicity of certain functional groups or, more 
generally, the chemical reactivity might be helpful. Other useful 
further parameters could be, for example, chelating power, sur-
face tension, oxidizing properties, and so on. The scope may in-
clude data from related areas, such as environmental fate data, 
in particular ready biodegradability, because they are indicative 
of a possible biological similarity, even though not directly rel-
evant to the endpoint of interest. If not possible or too costly to 
obtain, there are programs that can provide relatively accurate es-
timations based on quantitative structure-property relationship 
(QSPR) models. Most of them are collected in the ECHA guid-
ance for the preparation of REACH registration dossiers in the 
sections on adaptations of the standard testing regime (ECHA, 
2017g). Others have been recently published, e.g., the OPEn 
structure-activity/property relationship app (OPERA; Mansouri 
et al., 2018) developed jointly by EPA and NICEATM and applied 
to more than 800,000 chemicals to produce freely available pre-
dicted properties on the EPA CompTox Chemicals Dashboard18. 
However, as these parameters are fundamental for predicting the 
biological activity of any substance, it is recommended, in gener-
al, to measure physicochemical properties with standard experi-
mental protocols rather than to use prediction models, if possible. 
When all available data are collected, they must be evaluated to 
decide whether they provide a clear picture and enough informa-
tion to conclude whether the comparison between the source sub-
stances and the target substance is accurate enough to permit a con-
clusion and fill the gaps as required. If the approach seems reason-
able but not sufficient to demonstrate the similarity, further tests on 
the category are necessary. The necessity to perform new in vivo 
tests should be considered at the very end of the process and only 
when all other opportunities have been considered. Gaps or uncer-
tainties should be filled with existing studies or new in vitro tests.
Computational tools assist the identification of source materials 
and the demonstration of similarity, which would ideally include 
both toxicokinetic and toxicodynamic (TK/TD) considerations. 
Computational systems can be applied to analyze the issue global-
ly, for example by defining the bioactivity profile through finger-
print description to feed machine learning models (Sturm et al., 
2018). A useful database that can facilitate read-across groupings 
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profilers and to establish response-to-response relationships.
7. A means of developing and justifying targeted and efficient 
testing and assessment scenarios that save time and resources, 
e.g., by identifying data gaps.
8. A means of supporting assessments of combined exposure to 
multiple chemicals within and across AOPs.
9. Greater biological context to what is currently a statistically 
based approach.
Even though AOPs, as presented in the AOPwiki21, incorporate 
a useful framework for comparing two or more chemicals and 
also a starting point for building the experiments for the biolog-
ical demonstration of similarity (Nelms et al., 2018), sharing the 
same AOP may only demonstrate the possible biological activity 
but says nothing about whether this effect really occurs and does 
not provide an indication of the doses that may activate the ef-
fect, which is fundamental in chemical risk assessment.
The EU-ToxRisk Project is developing conceptual frameworks 
to integrate NAMs for RAx assessment (Escher et al., 2019) and 
in particular on how NAM testing can prove the RAx hypothesis 
(Fig. 5). This concept has been developed through learnings from 
several case studies in which in vitro and in silico models are used 
to support the analysis of TD/TK properties, with a strong link be-
tween grouping and AOPs.
In the future, NAMs in combination with RAx represent a 
strong possibility to dramatically reduce or even eliminate the 
need for new in vivo testing. This will happen when the develop-
ment of in vitro testing is mature enough to fill the data gaps in the 
categories (Fig. 4).            
that lead to an adverse health or ecotoxicological effect (Ankley 
et al., 2010; Stiegler et al., 2011; Becker et al., 2015; Dreser et al., 
2015). The AOP concept is very similar to the pathway of toxici-
ty (PoT) concept (Kleensang et al., 2014). AOPs provide a useful 
framework for comparing two or more chemicals and also a start-
ing point for building the experiments for the biological demon-
stration of similarity (Nelms et al., 2018). In the definition of an 
endpoint, NAMs can be organized in an IATA that represents how 
the different approaches are combined within a regulatory context 
to reach a final conclusion on the hazard characterization of a sub-
stance20 (Leist et al., 2014). 
The idea to apply the AOP principle to organize information was 
first proposed during a workshop at the OECD organized in 2010 
(OECD, 2011). Members of a category should share the same mo-
lecular initiating event (MIE) and the same metabolic pathways 
(Cronin and Richarz, 2017). According to these authors, the role 
of AOPs to support RAx can be summarized as:
1. A plausible and transparent means of linking MIEs to the in 
vivo outcomes of regulatory interest and making uncertainties 
explicit.
2. A qualitative means of establishing causal linkages.
3. A conceptual framework for organizing information at differ-
ent levels of biological organization, characterizing the WoE.
4. Evidence supporting the robustness of chemical categories.
5. A means of forming categories based on both intrinsic chemi-
cal and biological activity.
6. A basis for testable hypotheses, which in turn leads to the de-
velopment and use of in vitro databases for developing new 
Fig. 4: Inclusion of NAM-derived data 
in RAx justification dossiers to build 
confidence in its regulatory use 
(i) A registration dossier based on RAx 
always contains a justification including 
data that prove the validity of the similarity 
hypothesis and/or the reliability of the 
in vivo studies performed on the source 
compound. Recently, NAM-derived data 
have started to be used as complimentary 
information to support the RAx hypothesis. 
(ii) An increasing confidence in the use of 
NAM-data may lead to their exclusive use 
for similarity definition, category formation, 
and to fill data gaps (in case of lack of in 
vivo data). (iii) As short-term effect, the use 
of NAM-derived data in RAx dossiers can 
increase the regulatory acceptance rate 
of RAx justifications in risk assessment. 
As long-term effect, the increasing 
confidence in such data could lead to a 
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the distribution of a substance in the organism can also indicate a 
possible target organ. Here NAMs can be supported by quantita-
tive in vitro to in vivo extrapolation (QIVIVE), even though there 
are still no valid and universally applicable systems (Hartung, 
2018; Kisitu et al., 2019). Excretion mode and kinetics represent 
other parameters affecting systemic uptake and exposure, and they 
should always be considered to conclude on the similarity among 
the components of the category.
Metabolism is one of the most important steps of the ADME 
process. RAx studies where the source and target compounds 
share the same active metabolites are an infrequent but fortunate 
situation, allowing an easy justification of the RAx approach (van 
Ravenzwaay et al., 2016). In general, dissimilarities in metabo-
lism will considerably complicate the RAx, since this would trig-
ger the need to demonstrate the absence of (relevant) toxicity for 
all metabolites not common to both source and target chemicals. 
Metabolism assessment can be performed through a new exper-
imental in vitro study, for example with primary hepatocytes, 
which can provide an idea of clearance and transformation. Un-
fortunately, an exhaustive analysis of metabolism requires long 
and expensive studies, and it is hardly ever performed outside of 
pharmaceutical and agrochemical applications. To cope with the 
lack of experimental data, chemoinformatics may help to provide 
a prediction of metabolism products (Madden and Cronin, 2006; 
Kirchmair et al., 2015; Djoumbou-Feunang et al., 2019; Miller et 
al., 2019). Computational metabolite predictions represent a valu-
able tool that may identify outliers in a group of similar substances 
or explain differences when in vivo animal studies are applied to 
the situation in humans.
The EU-ToxRisk project is taking up the challenge of ADME, 
being aware that, in many cases, lack of demonstration that tar-
get and source substances are similar was the cause of rejection 
of the RAx justification by regulators (Ball et al., 2016). The RAx 
is acceptable only if sufficient similarity in ADME properties be-
tween source and target chemicals is demonstrated and the possi-
ble impact of any dissimilarities is sufficiently explained. The ab-
sence of reliable ADME information often represents one of the 
weakest points in RAx justifications, and in this regard it seems 
fair to note that by not making ADME data a mandatory standard 
requirement, the REACH Regulation has put a major hurdle in the 
way of achieving its own goals in terms of facilitating the move 
away from in vivo animal testing.
2.4  Applicability domain of RAx
The ECHA RAAF document is very explicit in limiting RAx to a 
single endpoint (ECHA, 2017b,c). On the other hand, the success 
of RAx depends on a more holistic approach facilitated by the 
analysis of large quantities of data. Even though the final goal is 
the prediction of the specific endpoint, this always should be con-
nected to a more general analysis of all possible analogues and 
groups of chemicals.
Enoch et al. (2008) demonstrated that reliability of QSARs is 
improved when modelling the individual mechanisms of toxic ac-
tion present in the data set. The link of the prediction to the full 
elucidation of the mechanism provides specific limits to the pre-
diction, with a precise definition of the boundaries for the group of 
2.3  Absorption, distribution, metabolism 
and excretion (ADME)
ADME profiling represents an important step of RAx justifica-
tion and, in particular, for moving from hazard to risk assess-
ment. ADME also can be useful to select source substances.
To complement this information, both the source and target sub-
stance need a proper characterization of ADME data (Tsaioun et 
al., 2016). Unfortunately, outside of the pharmaceutical and agro-
chemical sector, this information is at best partially available from 
dedicated experimental studies. 
Differences in absorption rate and distribution can be consid-
ered in RAx for risk assessment purposes, and big differences may 
be considered a pointer towards more important dissimilarities be-
tween chemicals, while the demonstration of similar absorption 
and distribution may support the RAx justification. Information on 
Fig. 5: Workflow describing the RAx framework developed and 
applied within the EU-ToxRisk project
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the scope of RAx, the only way to demonstrate that a specific sub-
stance activates no toxicological alert should be supported by ei-
ther a higher number of source substances, all demonstrating bio-
logical inactivity, or a strong demonstration of similarity if there is 
only one source substance. As far as possible, the latter case should 
always be supported by a further demonstration that “biological 
surprises” appear unlikely, for example by providing evidence for 
similar substances. A way to tackle uncertainty is by using a set 
of independent information that leads to the same conclusion in a 
WoE approach (Linkov et al., 2015). Schultz et al. (2017a) have 
provided a good example with the analysis of a set of n-alkanols, 
which were analyzed by grouping substances sharing common ab-
sorption profiles and metabolic pathways, confirmed by the exis-
tence of good 90-day oral repeated dose toxicity studies in rats. 
In conclusion, general rules for RAx validity are applied also 
for demonstration of the absence of biological concern, with a fur-
ther detailed description of ADME and all possible MoAs/AOPs 
that may occur. In the future, omics profiling or high-throughput 
testing schemes such as the Tox21/ToxCast program might aid in 
demonstrating a lack of biological activity over a broad range of 
effect markers. 
As reported in other sections, the amount of information consid-
ered sufficient depends on the risk that is related to the assessment 
together with the regulatory application scope and should be con-
sidered on a case-by-case basis. The principles described to reduce 
the uncertainty are generally valid, but they should be applied 
even more rigorously for the definition of the absence of concern. 
More specific guidance would be helpful here.
2.6  Hazard characterization and potency
A comparatively easy application of RAx is hazard identifica-
tion by means of a demonstration that two or more chemicals 
may qualitatively exhibit the same toxicological effect. In con-
trast, the prediction of potency, e.g., in the form of a classifica-
tion sub-category, places considerably higher demands. Hazard 
characterization is communicated to all users with specific picto-
grams and hazard phrases, as internationally agreed by the Unit-
ed Nations in the Globally Harmonized System of Classification 
and Labelling of Chemicals (GHS), which was implemented in 
the EU with the Classification Labelling and Packaging (CLP) 
Regulation (EC) 1272/2008, which explicitly accepts RAx when 
describing the scope of WoE determination in its Annex I.
The difficulty in applying RAx for classification purposes lies 
in the analysis of potency for the determination of hazard cate-
gory. Categories of local effects are generally well characterized 
with defined thresholds, while more concerning endpoints, such 
as CMRs (carcinogenic, mutagenic and reprotoxic substances), 
have no defined threshold in CLP, and the category is demarcat-
ed only by the qualitative probability that a substance may exert 
that effect. In fact, Category 2 is based on the presumption that 
the toxicity outcome may result, Category 1B is the proven tox-
icity in animals, and Category 1A the proven toxicity in humans. 
In all cases, there is a need to assign a dose to the hazard, which is 
a defined threshold for local and acute toxicity endpoints and the 
no-observed-adverse-effect-level (NOAEL) for the systemic end-
points, for risk assessment.
chemicals in RAx, including the applicability domain. The one-to-
one comparison, i.e., one target and one source chemical, should 
be applied only in case of very strong evidence of similarity and 
identical biological activity. Rather, any demonstration of similar-
ity should benefit from a global analysis that includes not only a 
larger set of chemicals but also the assessment of general toxici-
ty of the substances, with a possible explanation of the differences 
that may derive also from physicochemical properties.
The concept of local validity (Patlewicz et al., 2014) can be ap-
plied in reverse mode. The explanation of a possible mechanism 
can set the boundaries for the applicability domain of RAx by im-
posing the use of a specific method to substances that show a spe-
cific mechanism or that are metabolized to a specific chemical.
The mechanistic applicability domain is one important aspect, 
but the structural and physicochemical descriptors, as well as 
property and effect spaces also need proper attention when build-
ing a category. Overall, the applicability domain of a RAx catego-
ry can be considered a multidimensional space composed of all 
these elements, in which members of a valid category are locat-
ed relatively “closely” to each other. In case of even distribution 
of the category members, trust in RAx categories is increased if 
the category encompasses a densely populated multidimensional 
space and the target compound is located in such an area.
2.5  RAx for non-classified substances
Declaring the existence of a certain risk of toxicity for a substance 
is comparatively easy, even though there is always the possibility 
of a hidden risk of higher concern. The situation is different when 
the RAx exercise aims to demonstrate the absence of concern, 
because this conclusion should really include the demonstration 
that any possibility of hazard has been taken into account. For 
this reason, RAx for substances with no or low activity requires 
more comprehensive justification, supported by a high level of 
confidence and strong evidence. At the same time, most chemi-
cals do not seem to require hazard classification (Hoffmann and 
Hartung, 2005; Luechtefeld et al., 2016a), and therefore it may 
be expected that the number of RAx resulting in a “negative”, 
i.e., absence of relevant effects, outcome will be clearly higher 
than that of RAx predictions with a “positive” effect.
The big question is how to achieve sufficient confidence in neg-
ative conclusions on toxicity. It is a truism that scientific knowl-
edge develops over time, and the regulatory landscape will con-
tinue to change based on the discovery of new or a re-evaluation 
of known mechanisms and effects of chemicals in biological sys-
tems. Therefore, the natural answer to the above dilemma could 
be that predictions of a general absence of toxicity should cover 
all areas of potentially adverse effects known and considered rele-
vant in the respective legislative framework at the time the predic-
tion is performed. Under REACH, for example, the range of end-
points to consider in general is characterized by the output of the 
methodology accepted for the generation of the standard informa-
tion specified in Annexes VII-X, even though it should be enlarged 
in situations where there is a reason to assume that the standard in-
formation is not sufficient. As a consequence, confidence, wheth-
er in traditional assessment or RAx, is best increased by consid-
ering a wide range of endpoints with in-depth TK/TD analysis. In 
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missions, it does indicate that RAx has been applied in a number 
of scenarios and with a variety of techniques. Turning some of 
these into case studies is useful for a number of reasons that go 
beyond simply providing an illustration for further use (Tab. 1). 
For the illustration of RAx in various forms, the OECD has pub-
lished case studies on the applicability of IATA including RAx 
(OECD 2016b, 2017b, 2018). These examples perfectly demon-
strate the new idea of risk assessment as a combination of QSAR, 
RAx, NAMs and WoE. The way they are presented is not intended 
to provide exhaustive documentation to justify the RAx approach, 
but rather to analyze the state-of-the-art of this methodology, with 
particular attention to strengths and pitfalls. The focus is on one or 
more specific endpoints such as mutagenicity, repeated dose toxic-
ity, etc. and not so much on the categories themselves.
As part of the SEURAT-1 initiative, RAx case studies were in-
stigated (Berggren et al., 2015). This resulted in the development 
of a template for reporting RAx (Schultz et al., 2015) as well as the 
publication of some of the findings in the peer-reviewed literature 
(Schultz et al., 2017a,b; Mellor et al., 2017). Analysis of the case 
studies overall allowed Schultz and Cronin (2017) to provide prac-
tical examples on how to reduce the uncertainty related to the RAx 
assessment, concluding on the importance of data quality, similari-
ty argumentation and justification, and the overwhelming need for 
TK/TD data (Pamies et al., 2018). These analyses later influenced 
the description of the overarching uncertainties associated with 
The OECD guidance on grouping of chemicals provides some 
consideration on how a quantitative prediction for target substanc-
es can be made by extra- and interpolation within a category for 
which trend(s) in toxicity or factors influencing toxicity have been 
identified. When the AOP and quantitative information on the re-
lationship between KE and AO are known, NAMs can be used for 
the target and source substances to further strengthen the (quanti-
tative) prediction, with the application of a suitable QIVIVE cor-
rection. While larger categories might provide the basis for trend 
analysis and thus a relative potency assessment of their members 
regarding a specific effect, the situation is much more difficult in 
one-to-one assessment, and additional reasoning will generally be 
required to assign the same, or a higher or lower, potency to the 
target. Depending on the legislative framework, the assignment of 
additional assessment factors (AF) might be required in such cir-
cumstances. A more scientific approach could consider a detailed 
toxicokinetic assessment with correlation of the exposure and the 
concentration at the target site. 
This particular topic clearly needs more discussion and agree-
ment between regulators. 
2.7  Practical case studies
The published literature gives an indication of the considerable 
breadth of RAx studies that have been undertaken and reported. 
Whilst this is not necessarily representative of all REACH sub-
Tab. 1: Some examples of available public case studies on the applicability of RAx for regulatory purposes,  
as described in the text
Projects Description Main documents




















IATA Case Studies  
Project  
(2015-current)
The project aimed to improve the information used to decide on the needs 
for further regulatory risk management with the involvement of Member State 
competent authorities and concerned registrants. Two different elements were 
tested: addressing substances by groups and early interaction with registrants. 
The project demonstrated an increase in effectiveness, providing a better  
picture of the gaps and the points of concern.
The primary goal of the read-across case study within the project was to increase 
confidence in the read-across assessment by using data from alternative 
methods. The CS were run under 2 conditions: read-across without additional 
new approach data; addition of NAM data (primarily from ToxCast  
and from application of the alternative methods developed within the initiative). 
In the EU-ToxRisk project, the Read-Across Case Study Strategy includes 
assessment of toxicokinetics, both in the in vitro experimental set up and the 
extrapolation to safe human doses. These are integrated into the design of  
EU-ToxRisk case studies through the use of ADME models and generation of 
ADME in vitro data. The results of the NAM-supported read-across case studies 
are compiled and sent for evaluation to regulators as a “mock submission”.  
The experience and learnings gained during the project will be compiled in a 
NAM-based read-across guidance. 
The objective of the IATA Case Studies Project is to increase experience with the 
use of IATA by developing case studies, which constitute examples of predictions 
that are fit for regulatory use. The aim is to create a common understanding 
of using novel methodologies and the generation of considerations/guidance 
stemming from these case studies. Case studies submitted by OECD member 
countries are reviewed regularly. Learnings and lessons derived from such 
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RAx, allowing for a series of questions to probe the quality, or oth-
erwise, of the underpinning science and data (Schultz et al., 2019).
The EU-ToxRisk Project has started an initiative in collabora-
tion with regulators from different scientific areas, including ex-
perts in the areas of pesticides, food safety, industrial chemicals, 
etc. Partners have prepared mock submissions to regulators from 
agencies associated with European regulations in order to learn 
whether their approaches would be acceptable in a legal context 
or not. In this way, EU-ToxRisk case studies are treated as if they 
were real cases with the purpose of challenging the traditional reg-
ulatory assessment approach. A dedicated workshop with the ac-
tive collaboration of ECHA and EFSA has already taken place22, 
and the final report should be published in 2020.
In recent years, also ECHA and the EU Member States have in-
creasingly included grouping approaches into their screening and 
assessment schemes. In particular, ECHA launched the collabora-
tive approach (COLLA) pilot projects focused on five groups of 
substances (ECHA, 2018). The aim was to improve the informa-
tion used to decide on the needs for further regulatory risk man-
agement with the involvement of Member State competent au-
thorities and concerned registrants. The projects explored how the 
overall grouping approach can be used to clarify and address the 
identified concerns and what type of supporting information is re-
quired. The projects tested two different elements: addressing sub-
stances by groups and early interaction with registrants. It was re-
ported that the resources spent by ECHA and Member State au-
thorities were significant, and almost equally divided between the 
screening and the interaction phases. The COLLA could demon-
strate an increase in effectiveness, providing a better picture of the 
gaps and the points for concern, while it was difficult to conclude 
on benefits in efficiency due to the amount of resources required in 
the management.
In the scope of REACH, other simple approaches have been 
used in the area of metal salts, e.g., for nickel, cobalt, iron chlo-
rides, sulfates, nitrates, etc. More complex RAx categories have 
been built for petroleum/coal products, fatty acid derivatives, etc. 
With the exception of a few publications (Clark et al., 2013) or 
indications on the consortia website such as CONCAWE23, these 
data mainly derive from the personal experience of some co-au-
thors and are generally not public. Further analysis is not possi-
ble and, moreover, the general feedback from the authorities is not 
known, unless looking for data relative to the submission of the 
individual substances. Even though it would be interesting, this 
search is out of the scope of this publication.      
2.8  Integrated use of RAx 
The main potential of RAx lies in its application in an integrated 
way on several source substances, so it is more than a simple tool 
to waive a single in vivo test. Rather, the assessment relies on a 
more global approach that considers a variety of data. Even if the 
comparison can be between one source and one target, the use in 
support of many other chemicals in a group or the comparison be-
tween other similar substances can be of benefit. Let us consid-
Fig. 6: Decision strategy for the application of a RAx 
framework for risk assessment 
After the definition of the target substance and the identification of 
data gaps, the first step is the identification of all possible source 
substances with the support of QSAR tools. The process proceeds 
only if it is demonstrated that target and source substances 
share a similar toxicological profile. A full characterization of the 
physicochemical properties and the experimental determination of 
basic biological endpoints, such as those required in Annex VII of 
REACH, can support this step. The NAM-enhanced RAx benefits 
from the performance of suitable in vitro tests that can provide 
mechanistic information for biological similarity or elucidation of 
ADME. The whole procedure moves forward in an iterative way. On 
the other hand, if RAx is confirmed, the last step is the compilation 
of the RAx report that should contain all details of the steps and the 




ALTEX 37(4), 2020 593
to increase the objectivity of the final outcome and to guarantee that 
all available data and information is taken into consideration. The 
analysis of dossiers containing RAx justifications that have been re-
jected by the authorities can be very useful to understand the regu-
latory requirements of an application (Ball et al., 2016).
3  Regulatory use of RAx
3.1  Validation 
Validation of the RAx approach represents the best opportuni-
ty for regulatory acceptance and the necessary step for reduc-
ing uncertainties and building scientific confidence. More spe-
cifically, method validation is a process designed to show that a 
given method is adequate and reliable for the purpose it was de-
signed for. The requirement of validation is a direct consequence 
of the scientific method and addresses many of its fundamental 
aspects, e.g., hypothesis formulation, hypothesis testing, predic-
tions based on hypothesis, replicability, bias, uncertainty, etc. If a 
method has not been validated, this means, in effect, that it is un-
known whether it successfully serves the purpose it was designed 
for. The usefulness of such a method is then subordinate to sub-
jective beliefs. This is a criticism brought forward also against the 
currently applied in vivo methods, most of which were never for-
mally validated but which are still used in risk assessment follow-
ing conventional scientific acceptance. 
Regarding RAx, its validation should demonstrate that the ap-
proach leads to the expected result, e.g., that toxicological ef-
fects (or their absence) as observed in traditional in vivo or in vi-
tro tests are correctly predicted within reasonable limits. RAx is 
not per se a defined method, and therefore it cannot be validat-
ed following the procedure that is traditionally applied for in vitro 
er a very easy example of the RAx of a sodium salt (source) with 
its acid. If the dissociation constant confirms that the acid is ful-
ly dissociated at the physiological pH, such information already 
might seem enough to justify the read-across. However, the hy-
pothesis would be strengthened further if there is the possibility to 
compare other experimental endpoints for both substances, high-
lighting differences that may derive only from the capacity of the 
acid to alter the pH. It would not be surprising if the acid was clas-
sified as an irritant and the salt was not, but they may share identi-
cal biological behavior with regard to mutagenicity, developmen-
tal toxicity, etc. RAx hypothesis supported by other similar sub-
stances, with data on both the acid and the sodium salt, and even 
other salts, would then appear much stronger. 
In a more complex situation, the application of RAx requires a 
holistic approach that considers a multitude of data gained from 
both the target and the source substances. In Figure 6, the process 
for the demonstration of similarity is described. Such process is 
based on:
1. Similar chemical structure and behavior;
2. QSAR prediction;
3. Collection and evaluation of existing in vivo studies;
4. Assessment of new in vitro tests to confirm the mechanism.
If the RAx hypothesis is based on the hypothesis of the same TK/
TD profile, strong RAx justification should include, if possible 
(Fig. 7):
– Comparison between two substances sharing the same meta-
bolic products;
– Comparison with the substance representing the metabolic 
product itself; 
– Comparison with a group of similar substances showing a com-
parable metabolic trend. 
From this perspective, RAx is much more than the comparison of 
two chemicals to waive an in vivo test, rather it is a complex sys-
tem that studies toxicity in a highly integrated manner (Fig. 6). 
The final goal is an increase of knowledge on the toxicological 
profile of substances. This principle is well described in the EFSA 
document on WoE (EFSA, 2017). The EFSA guidance defines 
three steps for the WoE approach, i.e., assembling the evidence in-
to lines of evidence of similar type, weighing the evidence, and in-
tegrating the evidence. The three key parameters are i) reliability, 
as the extent to which the information comprising a piece or line of 
evidence is correct, ii) relevance, as the contribution answering a 
specified question, and iii) consistency, as the compatibility of the 
different information towards the final toxicity prediction.
Regarding new in vitro tests, those should be tailored to the spe-
cific need, whether it is the demonstration of a shared KE within 
an AOP or a TK/TD route. Other tests should be considered, such 
as the fish embryo toxicity (FET) test, if there is an issue related to 
developmental toxicity (Kroese et al., 2015). The selection of the 
right method should consider the applicability domain, the regu-
latory scope, and also other practical constraints, such as exper-
imental availability and costs, with the latter probably being the 
main obstacle to wider use of these new tools.
At the moment, this procedure is based mainly on expert judg-
ment, but the inclusion of defined approaches, i.e., testing strategies 
with clearly specified information sources and objective data inter-
pretation procedures, is highly recommended for the future in order 
Fig. 7: Scheme for the identification of possible source 
substances in a RAx approach
Given the target substance T, possible source substances are  
(i) substances producing the same metabolite M (parent substance 
P) but also (ii) the metabolite itself (target metabolite M). This 
pattern can be confirmed if other substances present the same 
trend in a category, where substances A1, A2, etc. (iii) metabolize 
to give metabolite M1, M2, etc., which can also be grouped together 
(iv). Availability of existing in vivo studies may be random in such  
a scheme. Nevertheless, they may predict the possible effect of 
target substance T with a high level of confidence.
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QSARs (OECD, 2007). For the specific case of RAx, these can be 
interpreted as follows:
– A defined endpoint. RAx assessment should be performed for 
each endpoint for which sufficient data are lacking. Often there 
is the danger of considering the RAx globally, without a clear 
definition of the specific activity that it is required.
– An unambiguous algorithm. This has to be applied to all algo-
rithms that are part of a RAx, e.g., those used for similarity as-
sessment or for weighing information in the context of a WoE 
decision. The procedure for RAx should be clear, transparent 
and reproducible, i.e., different experts should arrive at compa-
rable conclusions based on the same set of data. 
– A defined domain of applicability. As noted above, in RAx the 
applicability domain is characterized by the structural, mech-
anistic and property space spanned by the category members, 
while the resulting prediction is subject to the boundaries de-
fined by the regulatory scope of the requested assessment. How-
ever, this step should address also the adequacy of the available 
information. Proper characterization of the applicability domain 
will also help to identify potential bias in the selection or char-
acterization of the tested substances.
– Appropriate measures of goodness-of-fit, robustness and pre-
dictivity. For the RAx, being an individual and case-specific as-
sessment, performance statistics cannot be obtained, but this 
should be done for all non-standard methodology, e.g., in vitro 
and in silico NAMs, used to obtain the overall RAx conclusion 
(Bal-Price et al., 2018). Evaluation of robustness should include 
also the suitability and quality of the available information, e.g., 
if there is bias in the characterization of the tested substances.
– A mechanistic interpretation, if possible. Where available, mech-
anistic information is extremely helpful to strengthen the plausi-
bility of a RAx, with NAMs possibly applied for that purpose.
These points should be addressed via a solid assessment of the 
available data, methods using pre-defined criteria, and rules that 
are standardized and harmonized on an international scale as far 
as possible. Subjective expert judgement should be avoided as 
much as possible; where it is needed, a set of transparent, pre-de-
fined criteria and rules should be applied.
An opportunity to guide RAx validation starts from the definition 
of the different types of RAx that are applicable. The ECHA RAAF 
document (ECHA, 2017b,c) provides a good definition of the six 
possible scenarios: scenarios 1 and 2 refer to one-to-one read-across 
(analogue approaches), scenarios 3 and 4 to category approaches 
with variation in the properties observed among the source substanc-
es, and scenarios 5 and 6 to categories without such variation. The 
ECHA document explains in detail the basis for the RAx hypothesis 
that backs each scenario, with a list of pre-requisites that the submit-
ter needs to fulfil for the acceptance of the correspondent RAx strat-
egy. Based on these scenarios, assessment elements can be defined 
by constructing a set of questions that should be addressed to chal-
lenge adequacy, relevance and reliability of the RAx performed, in 
other words, its scientific validity. The answers given to those ques-
tions should arrive from a mix of computational systems and expert 
judgement, with the dilemma in setting the border between the two. 
tests24. Also, each RAx is a case-specific assessment combining 
purely computational tools with a mix of chemistry, mechanistic 
knowledge, QSAR, in vivo and in vitro techniques, brought to-
gether under the auspices of expert judgement. Source and target 
substances can be unique or multiple, and the endpoint compari-
son can be based on the same value or following a trend. The qual-
ity and amount of source data are also variable. Nevertheless, the 
adequacy, reliability and relevance of individual test or prediction 
methods combined in a RAx argument can be assessed, as can the 
overall plausibility of the RAx justification along with the extent 
to which uncertainties remain.
In many cases, the RAx approach is performed manually by an 
individual, or group of, toxicologist(s) (Benfenati et al., 2016). 
Although standardized RAx workflows (similar to a “defined ap-
proach” (DA) as used by the OECD, i.e., a defined set of informa-
tion sources assessed with a defined data interpretation procedure) 
or even automated RAx would appear a good option for provid-
ing an impartial output that is always repeatable and independent 
of the operator, fully automated assessment should not be run in 
an unsupervised mode. The best option should be somewhere in 
the middle, i.e., a standardized/automatic evaluation of particular 
criteria supporting expert judgement and evaluation providing per-
formance indicators for expert review but not necessarily an over-
all opinion. Even then, the best diagnostic tools will have little 
value unless they are used by operators who are familiar with the 
RAx technique as well as the underlying toxicology and chemis-
try of the specific case and the context-specific criteria for scien-
tific validity. For example, the most recent version of the OECD 
QSAR Toolbox16 supports the user by providing information on 
alert performance based on the category candidates that are select-
ed (Yordanova et al., 2019). Recently, Luechtefeld and co-work-
ers (2018a) attempted this task using an automated RAx-based 
QSAR approach on a huge set of acute and topical toxicity as well 
as ecotoxicological endpoints. They showed that on average a giv-
en self-classification in REACH registration dossiers could be re-
produced with a RAx-based QSAR model based on the nearest 
neighbors of that chemical in descriptor space with higher reliabil-
ity than was found for traditional test results in the REACH data-
base. Notably, this work focused on a simple GHS/CLP classifica-
tion endpoint, whereas such work currently cannot be realized for 
complex, multiple-endpoint systemic toxicities, even though some 
authors see such methodology as promising in the future, and this 
possibility should be kept open (Berggren et al., 2015). 
Many aspects of RAx are subjective and difficult to quantify. 
For instance, the evaluation of similarity is very challenging, and 
minor differences that seem negligible may have a strong impact 
on the biochemical activity, as illustrated by the problem of activ-
ity cliffs. If there was agreement on suitable metrics and on mini-
mum thresholds, this could be used as one of the parameters defin-
ing the applicability of a given RAx.
Moving to a possible practical approach, aspects of RAx ade-
quacy, reliability and relevance can be analyzed, as already pro-
posed for the validation of testing strategies (Rovida et al., 2014), 
by using the five OECD Principles established for the validation of 
24 https://ec.europa.eu/jrc/en/eurl/ecvam/alternative-methods-toxicity-testing/validation 
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ty, even though often disregarded in the validation processes. As-
sessment of uncertainty and confidence in RAx prediction should 
be a specific element of the RAx workflow. A defined and unique 
method to assess uncertainty does not exist. However, several ap-
proaches and frameworks have been proposed, with subjective 
and “expert-driven” methods, i.e., relying on expert judgment 
to evaluate the relevance of the analogues, their underlying da-
ta and the whole RAx argument (Blackburn and Stuard, 2014; 
Schultz et al., 2015), or by proposing more objective quantita-
tive approaches for assessing uncertainty (e.g., Shah et al., 2016). 
There is no “best” approach, especially considering that each 
RAx study should be assessed on a case-by-case basis, depend-
ing on the different scenarios, the hypothesis, and the rationale. 
However, it is important to follow a structured framework and 
to analyze and combine all the uncertainties for each step/ele-
ment of the RAx workflow to finally derive overall confidence in 
the RAx prediction. Qualitative ranking (e.g., low/medium/high) 
may be helpful, but the final impact should be carefully weighed. 
Automated RAx approaches have the advantage that a certainty 
of prediction can be assigned depending on the available source 
data quantity and quality, heterogeneity, and degree of similarity 
to the target structure (Luechtefeld et al., 2018a).
Uncertainty is embedded in all scientific measures and decisions. 
For traditional in vivo toxicity studies, this has been addressed late-
ly (WHO, 2018) but not yet solved, the report making the follow-
ing observation “the evaluation of uncertainties in risk assessment 
is a crucial issue, with direct consequences for risk management”. 
EFSA (2018b) recently published a key document on uncertainty 
analysis in risk assessment defining the uncertainty in toxicologi-
cal assessment as “all types of limitations in available knowledge 
that affect the range and probability of possible answers to an as-
sessment question”. A first distinction is made between uncertain-
ties associated with assessment inputs and those associated with 
assessment methodology, where both are applicable to the case of 
The definition of a case study that is assessed by different teams 
to refine the approach until the same conclusion is shared may rep-
resent a good exercise for validation. The main difficulty of this 
approach is that it is well known that the conclusion on risk assess-
ment is already different when performed by different experts even 
if the evaluation is based on the same set of in vivo studies (Ruden 
et al., 2001). Quality of source data is also a fundamental parameter 
to be considered in a validation process. A number of quality scor-
ing tools are available for this goal (Samuel et al., 2016).
Validation is useful only if universally recognized, in different 
countries and by different agencies, considering that the regulato-
ry endorsement is necessary for final acceptability. The challenge 
in this sense is not restricted to the validation of RAx. In many cas-
es, there is a lack of consistency between different assessors. Bear-
ing in mind that at this stage a global validation of RAx is practi-
cally impossible, efforts should still be made to harmonize the ap-
proach and improve regulatory acceptability. 
As part of the GRAP, good reporting is an essential pre-requi-
site for a suitable assessment of adequacy, relevance and reliability 
(Hartung et al., 2019). The final report should include all essential 
information on how the assessment was performed, with a clear in-
dication of the parameters that were applied. The assessor should 
be capable of repeating all the steps that were performed and con-
trol possible sources of bias and errors. Schultz et al. (2015) have 
prepared a comprehensive analysis of the main elements that 
should be included in a RAx report, with particular emphasis on 
the importance of a good organization of the data to increase con-
fidence and acceptability (Leist and Hengstler, 2018). Automated 
systems with their reporting templates may offer advantages here. 
3.2  Uncertainties
Even though part of the validation process, evaluation of uncer-
tainty deserves a dedicated section. In fact, it represents a key 
step to increase confidence and improve regulatory acceptabili-
Fig. 8: Tailoring the threshold  
of acceptable uncertainties based  
on RAx purpose
Different thresholds of acceptable un- 
certainties even though there are 
exceptions. In some situations, we may 
accept a high level of uncertainty in risk 
assessment if the margin of exposure (MoE) 
is large. Regulatory use of the RAx 
approach strongly depends on the 
regulatory framework for which it is used.  
The purpose will also define the 
acceptable level of uncertainty. For hazard 
identification and for the classification 
and labelling of a systemic effect, the 
acceptance may depend on the accuracy 
with which an effect within a toxicity area 
can be determined. In risk assessment, 
the demand on the acceptance of the 
uncertainty is higher.
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Tab. 2: Questions to assist in the identification of potential sources of uncertainty that may impair RAx prediction  
(Schultz et al., 2019)
1 The context of, and relevance to,  
the regulatory use of the read-
across prediction as defined by 
appropriate problem formulation
2 Type of category/group including 
the definition of the applicability 
domain 
3 The premise or hypothesis of  
the read-across
4 Mechanistic plausibility including 
completeness of the understanding 
of the MoA or AOP
5 Similarity in chemistry
6 Toxicodynamic similarity 
7 Toxicokinetic similarity
8 The quality of the apical endpoint 
data used to fill the data gap
9 The consistency in the effects  
and severity of the apical in vivo 
hazard and their concordance  
with regards to the intermediate  
and apical effects and potency data
10 Strength or robustness of  
the supporting data sets
11 The weight-of-evidence (WoE) 
supporting the prediction
12 Documentation and written 
evidence provided
– Is the regulatory purpose of the read-across prediction clearly defined? 
– Is the acceptable level or degree of uncertainty for the stated purpose defined? 
– Is the stated acceptable level or degree of uncertainty appropriate for the stated regulatory 
purpose? 
– Is the read-across approach (e.g., analogue or category) clearly reported? 
– Are the target and source chemicals clearly identified? 
– Is the applicability domain of the analogue or category defined? 
– Do target and source chemicals fit within the defined applicability domain?
– Is the hypothesis on which the read-across is based clearly stated and presented in sufficient 
detail to be assessed? 
– How clearly does the hypothesis state the chemical and biological mechanisms underpinning 
the toxic effect being read across? 
– Is there sufficient experimental information provided to support the proposed chemical and 
toxicological mechanisms? 
– How extensively does the experimental information provided support the mechanistic 
plausibility and/or the AOP or MoA on which the read-across is based? 
– Are the chemical structures (i.e., 2D structure, isomers, SMILES and molecular formula) 
reported for the derivatives used in the read-across? 
– Are the dissimilarities in chemical structure reported, and are they toxicologically relevant? 
– Are the relevant molecular and physicochemical properties (e.g., molecular size, 
hydrophobicity, solubility, volatility, degradation, etc.) reported for the derivatives used in  
the read-across? 
– Are the dissimilarities in molecular and physicochemical properties reported, and are they 
toxicologically (or pharmacokinetically) relevant? 
– Is there sufficient and consistent toxicodynamic information provided to establish similarity  
in the hazard of the derivatives used in the read-across? 
– Is there sufficient ADME information provided to establish toxicokinetic similarity for the 
derivatives used in the read-across? 
– Are any dissimilarities in ADME properties (and, as appropriate, metabolism/degradation) 
toxicologically relevant? 
– Is the performance (e.g., reliability, accuracy, precision, repeatability and reproducibility) of  
the data read across reported clearly?
– Has the quality of the data to be read across been assessed, and are they sufficient to meet 
the purpose of the exercise, i.e., complete and of sufficient quality? 
– Is the qualitative expression of the data reported, and is it consistent among the source 
chemicals? 
– Is the potency of the hazard reported, and is it consistent among the source chemicals?
– What are the temporal relationships between relevant endpoints? 
– What are the dose-response relationships between relevant endpoints? 
– How extensively are the relevant or key events either empirically measured and/or modelled 
by appropriate in silico, in chemico and in vitro data? 
– Is the performance (e.g., reliability, accuracy, precision, repeatability and reproducibility) of  
the supporting methods adequately reported? 
– Is there consistency in the supportive information (e.g., structural alerts) between analogues 
or within the category? 
– How many and how large are the dissimilarities in the supporting information (i.e., data gaps)? 
– Is the read-across prediction adequately documented? 
– Does the evidence support the hypothesis that the uncertainty is acceptable for the stated 
purpose (as per Question 1)? 
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endpoint gap that the RAx should fill. Some endpoints are charac-
terized by a well-defined mechanism and, as a consequence, the 
possibility of finding suitable source materials is easier. In con-
trast, for endpoints such as repeated dose toxicity, carcinogenicity 
or reproductive toxicity, the sources of uncertainty are broader and 
less quantifiable. The quality of source data and the unknown im-
purity profile of the test item is another source of uncertainty. Un-
certainty of RAx applied to UVCB substances is more challenging 
but still controlled if the evidence allows identification of the con-
stituents representing the main drivers of toxicity (EFSA, 2019). 
In case of high batch-to-batch variability in the composition of the 
UVCB substance, NAMs can provide high-throughput test arrays 
and omics methods to characterize the differences and guarantee 
the absence of possible concern.
For consistency of data, the risk to underestimate contradicto-
ry data or even exclude undesirable results is very high, and this 
is why the application of automatic tools is necessary to increase 
the confidence in an unbiased final conclusion. Careful evaluation 
of the available data is fundamental but often difficult when the 
source study reports are not available. 
Once finished with the analysis of available information, the fol-
lowing step is the justification of the similarity. While several tools 
are available to quantitatively compare two or more substances 
from a chemical point of view, this is not the case for the compari-
son of similar biological mechanisms, which nevertheless is highly 
desirable, even though it requires deep knowledge of the biological 
mechanism underneath the adverse effect. The level of uncertain-
ty can be further decreased by performing new experimental stud-
ies. Sometimes additional experiments might need to be carried out 
to determine the difference between two substances and to mea-
sure the trend of a specific property in a category, identify an activ-
ity cliff or provide bridging information, e.g., for QIVIVE (Fig. 9). 
This can be useful also to define the boundary of the category more 
precisely. The addition of information on physicochemical data can 
support the hypothesis (Helman et al., 2018) and highlight the pres-
ence of activity cliffs that may represent a serious source of errors. 
Estimation of metabolism is particularly important and should be 
performed very carefully, considering also that for the comparison 
of source and target substances, metabolism represents a means of 
similarity justification. It is generally difficult to assess the quanti-
tative relevance of predicted metabolites. Even though there is no 
way to exactly quantify uncertainty in manual RAx, extensive jus-
tification following the flowchart of Table 2 can help in the jus-
RAx. Regarding the acceptable level of uncertainty in light of the 
consequences, it is interesting that in addition to the possible im-
pact of the final decision on, e.g., health and economic factors, the 
urgency of a decision regarding the final goal of the risk assess-
ment might also need to be considered. Emergency assessments, 
e.g., after a spill of chemicals, sometimes have to favor fast meth-
ods over more reliable and sustainable ones. The EFSA Guidance 
comprehensively describes a methodology for identifying, assess-
ing, describing and, in some cases, quantifying uncertainty, provid-
ing some general principles applicable in the evaluation of RAx. 
Results must be expressed in an understandable way, but the con-
sumers of these results need to be receptive.
Frameworks such as the Dempster-Shafer theory allow for the 
combination of uncertainty from diverse sources and lead to rea-
sonable hazard estimates (Dutta, 2015; Rathman et al., 2018), 
even though other methods are also outlined in EFSA (2018c).
The regulatory use of the prediction and, in general, the final 
aim of the risk assessment should provide the level of uncertainty 
that is acceptable (Fig. 8). The process of substance prioritization, 
on the one hand, is probably the least demanding, as it is necessari-
ly followed by further testing. On the other hand, the evaluation of 
a cosmetic or a food ingredient with widespread use among con-
sumers requires much more care. If it is in the scope of a specific 
regulation, acceptability limits in the legislation text should be an-
alyzed in detail.
Schultz et al. (2019) reviewed six previously reported case stud-
ies with the aim of identifying uncertainties that potentially impact 
the acceptance of a read-across prediction. They identified a total 
of twelve sources of uncertainty and formulated thirty questions to 
assist in assessing uncertainties, as reported in Table 2. The answer 
to each of those questions may guide the applicants in the analysis 
of the uncertainty of the approach. This process needs a very robust 
approach to demonstrate objectivity and transparency (Schultz et 
al., 2015).
In the context of RAx, a major issue in terms of uncertainty re-
lates to the identification of source substances. This step should 
follow strict rules to guarantee that any available source is consid-
ered, with no exclusion based on the “cherry-picking” principle. 
Demonstration of a systematic and extensive search for analogues 
by means of a computer system may increase the reliability of the 
operation. Using a worst-case compound in a RAx scenario may 
help to reduce the uncertainty that the outcome could underesti-
mate the risk. Another aspect of RAx uncertainty is linked to the 
Fig. 9: Applications of NAM to reduce 
uncertainties in RAX justifications 
The same in vitro test is performed on 
all substances belonging to a category 
to demonstrate the similarity and identify 
possible activity cliffs. New in vitro methods 
are also used to identify metabolite patterns 
and to assess whether they are shared 
among the components of a category.
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ilar to those used by the OECD IATA case studies project (OECD, 
2016b), are helpful.
3.4  Tailoring to regulators’ needs 
Regulatory use of the RAx approach strongly depends on the 
regulatory framework under which it is used. For that reason, it 
is also important that the purpose for which the RAx is intended 
has a clear problem formulation, which could be, for example, 
classification and labelling, waiving a specific test, or to perform 
a risk assessment in the scope of a specific regulation. The pur-
pose will also define the level of uncertainty deemed acceptable. 
For classification and labelling related to a systemic effect, ac-
ceptance may depend also on the possible determination of the 
toxicity category. In risk assessment, less uncertainty also could 
be acceptable when there is only a small margin between the es-
timated exposure and risk levels or when sensitive populations 
such as children, elderly people or pregnant women are exposed 
(Fig. 8). Acceptance may also depend on whether it is intended to 
make a negative or positive RAx, in terms of CLP purposes. For 
a positive RAx, acceptance might be easier when made as a rea-
sonable worst case, whereas for a negative RAx more guarantee 
should be given that no effects are overlooked. So, the first step 
is always an in-depth understanding of the regulatory context as 
well as of the consequences of a wrong decision. 
Regardless of the scope, the most important regulatory aspect is 
the preparation of the RAx justification document, which not only 
should demonstrate the scientific validity of the approach but al-
so needs to follow the format specified in the relevant regulatory 
framework. 
4  Implementation
4.1  Capacity building 
Capacity building represents a key aspect in the promotion of 
RAx as a valuable tool for risk assessment. Individuals as well as 
organizations require the necessary skills to build a satisfactory 
strategy, decide on new tests and present results in a suitable re-
port. The required field of expertise is wide, covering chemistry, 
biology, toxicology, computational modelling, experience with 
the regulatory process and so on, which leads to the conclusion 
that the knowledge of a single person might not be able to cov-
er all aspects, and thus performing RAx and its assessment ade-
quately requires the activity of a team of experts.
That said, the concept of RAx in its more elaborated form is 
quite new in toxicology, and to the knowledge of the authors, there 
is no dedicated course at any university or good textbook available 
to explain how it works and how to use it. 
While there is a growing mass of literature published in peer-re-
viewed journals and considerable guidance from bodies such as 
OECD, ECHA, ECETOC, etc., there is no overall knowledge 
source. Books such as by Cronin et al. (2013) provide a sound ba-
sis to the theory, and recent papers such as Patlewicz et al. (2017, 
2018, 2019) include updates on the tools that may be applied. As-
pects of computational toxicology have been included in under- 
and postgraduate education for many years, from Bachelor level 
tification of similarity, even in case of absence of effects whose 
demonstration is always more difficult. In conclusion, uncertain-
ties can be reduced by appropriate and directed testing with a focus 
on TK/TD and the use of NAMs to support similarity justification, 
in many cases proving the same hazard class. 
3.3  Good Read-Across Practice (GRAP) 
GRAP represents an important opportunity to increase the reg-
ulatory acceptance of RAx by improving scientific plausibility. 
Ball et al. (2016) summarized the main steps to establish GRAP, 
starting from the collection of REACH registration dossiers con-
taining unsatisfactory RAx presentations. The most significant 
factor for rejection was the lack of sufficient supporting informa-
tion; this may be derived from poorly described scientific plau-
sibility and justification of the similarity argument, insufficient 
evaluation or analysis of the underlying toxicological data or in-
adequate substance identity profile. In order to meet regulatory 
expectations, improvement in the definition of the identity profile 
for both target and source substances as well as compliance with 
the regulatory needs could be achieved with the distribution of a 
suitable template to prepare a RAx justification document. One 
of the important aspects of GRAP is the regulatory scope for the 
applicability of RAx. In practical terms, this means understand-
ing the standard testing requirements of the framework as well as 
the specific provisions of how RAx may be applied to adapt those 
standard requirements.
A general rule for GRAP applicability is the description of each 
step of the RAx strategy to demonstrate that any possible source 
substance with correspondent available information has been con-
sidered with no bias in the selection or exclusion of source data. 
The procedure for profiling the target substance to obtain all avail-
able source data should be clearly defined to ensure that no rele-
vant study is discarded. After collecting the broadest set of infor-
mation, data gap-filling should be considered for a well-defined 
endpoint using a specified procedure. The way to use RAx may 
depend on the type of information collected, i.e., which scenar-
io selected from the RAAF document is applicable to the specif-
ic case (ECHA, 2017b,c). Filtering the available information and 
the re-organization to group it in order of relevance or mechanis-
tic steps should follow the final aim of the target analysis. This 
assessment is more complicated if it involves trend behavior that 
should be quantified in some way. Data collected on possible ana-
logues may lead to discordant results, or poor-quality source data 
may generate the necessity to deal with outliers and WoE analysis. 
From the perspective of GRAP, eliminating or downsizing the rel-
evance of a data set is a very sensitive step. It should be handled 
carefully and in the most transparent way to avoid the generation 
of increased bias and uncertainty in the final results.
At the end of the procedure, GRAP needs a residual uncertainty 
assessment with a detailed description of each single step to elim-
inate any doubt of subjectivity regarding the final outcome and 
make the final conclusion as reproducible as possible, applying the 
principle that the same set of data should give the same results in-
dependent of the proficiency of the operator.
As already mentioned, good final reporting is essential (Har-
tung et al., 2019). For this purpose, dedicated templates, e.g., sim-
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of inter- and multi-disciplinary workshops can foster communi-
cation among users, with possibilities of exchange of information 
between different fields or at the international level. 
Good information exchange requires free access to knowledge 
hubs, e.g., for tools, guidance, data, templates (Krebs et al., 2019), 
education, etc., and in this sense, international collaboration should 
be established to avoid duplication of efforts. Standardization of 
data-sharing should also improve the mutual acceptability of the 
methodology and increase confidence in the approach. Other areas 
suitable for standardization include the terminology used and rec-
ommendations for RAx justification. In addition, successful read-
across examples should be stored to avoid duplication and to act 
as a resource. Taking inspiration from the AOP knowledge base, a 
well-designed web resource and wiki may help with this. In order 
to improve knowledge and expertise among users, the best oppor-
tunity is to improve communication among stakeholders with the 
creation of databases, either at international or regional levels. This 
international coordination may also be used to identify gaps and 
concentrate efforts on the development of new computational tools 
or experimental methods.
4.2  Platforms 
It is clear that the availability of specific computational platforms 
is a prerequisite for a successful application of RAx, aiding in en-
suring the objectivity, reproducibility, and transparency of the out-
come. That is easy to say, but the applicability is not as clear. The 
first concern is the quality and homogeneity of source data, keep-
ing in mind the rule “garbage in, garbage out” and, therefore, cu-
ration of the available data may represent a key step. Another is-
sue to guarantee that different users arrive at the same conclusion 
is that algorithms applied in similarity assessment are equivalent. 
While the demonstration of chemical similarity can be easily auto-
mated (Luechtefeld and Hartung, 2017), comparison of biological 
data is more challenging. In addition to the quality of data sources, 
there is a total lack of harmonization in reporting the results. While 
some reporting standards for animal studies exist (Kilkenny et al., 
2014), this practice is only on the way for in vitro work (OECD, 
2017b; Hartung et al., 2019). Analysis of in vivo data is different 
to that of in vitro data. There is no standardization of units, rang-
ing from the simple mg or mole/weight expression to the differ-
ence in dose among in vitro, in vivo by gavage or in vivo through 
the feed. A possible solution could be a selection of data, for ex-
ample considering only GLP studies, but this procedure may trig-
ger other problems, such as the elimination of much important data 
and the need for detailed rules to accept/disregard data, and there-
fore introduce another variable that may bring with it errors, bias 
and/or increased uncertainty. Weighting of source data is essential 
and may represent a possible solution if performed in a transpar-
ent way. Principles and key elements for establishing a WoE for 
chemical assessment are contained in an OECD guidance docu-
ment (OECD, 2019) following ECHA, which published a template 
degrees to PhDs, while RAx as a subject has only recently been 
included in some academic curricula. RAx will form the core of a 
new master’s program in computational toxicology25. In general, 
this is not enough to train all aspiring toxicologists.
To make up for the shortfall in education and the desire to train 
practitioners, a number of courses are on offer. With the exception 
of regular training on the OECD QSAR Toolbox16, most courses 
are run as one-offs, either as commercial ventures or as continuing 
education courses at annual toxicology meetings. There is a need to 
formalize such training capacity to optimize opportunities and in-
crease capacity, for example, by using widespread platforms such 
as Coursera26. 
The use of video, e.g., YouTube, as a training means is very help-
ful to get across key messages. The OECD QSAR Toolbox has for 
many years provided on-line training in this manner27. Other re-
sources are available, e.g., for the US EPA’s Gen-RA tool. One pos-
sibility is to bring together all these resources to provide a central 
place to obtain up-to-date on-line training. This may also show up 
gaps where more training materials are required.
Many of the computational tools to support RAx typically pro-
vide good guidance, and specific training should be organized to 
improve their use, with the inclusion of examples, recommenda-
tions and so on. Users should have the capacity to identify a da-
ta gap with a view of how to solve it, whether it is the identifi-
cation of new source substances, improving TK/TD modelling or 
performing new tests to confirm a hypothesis. A combination of all 
available data with proper ranking and quality assessment also re-
quires new expertise.
Notwithstanding that certain data and copyright issues would 
have to be solved, a collection of real-life case studies to illustrate 
the key components of RAx would be extremely helpful. Ideally, 
these would highlight successfully submitted dossiers with a thor-
ough explanation of the key steps and how success was achieved. 
It is also helpful to demonstrate what caused rejection of RAx cas-
es, illustrating the reasons for non-compliance provided by the rel-
evant authority, as is the case when ECHA does not accept a RAx. 
Both “best” and “worst” practice examples are instructive and 
should be shared in the community of RAx performers and asses-
sors for educational purposes. 
The preparation of templates for RAx submission can also have 
a role in guiding new users through a proper application of the RAx 
approach, in particular if such templates are distributed with ex-
amples. Templates could also include the types of reporting for-
mats available from software, e.g., from the OECD QSAR Tool-
box16, and how these can be adapted and the information content 
improved. Such templates tend to be useful to store the information 
from the data retrieval exercise, even though expert knowledge is 
still required for the argumentation and justification of the RAx.
A key component of successful RAx is its multidisciplinary na-
ture. It is essential that scientists from all relevant disciplines are 
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is an open chemoinformatic system designed to support compa-
nies by facilitating chemical safety assessment. The AMBIT2 sys-
tem consists of a database including more than 450,000 chemical 
structures, the REACH dataset of 14,570 substances, as well as the 
EFSA OpenFoodTox database. It contributes to the safer use of 
chemicals and a reduction in testing and innovation cost by mak-
ing it easier for companies to comply with regulations governing 
chemicals. Several in silico prediction models (e.g., Toxtree, Ve-
ga) are integrated in AMBIT2. The import and export functions 
are enhanced in AMBIT2, which allows communication with a 
variety of additional prediction models such as knowledge-based 
expert systems for toxicity and metabolism.
The use of several computational tools (both commercial and 
free) can support the different phases of the RAx workflow, e.g.:
– tools/databases to search for potential analogues – by structur-
al similarity, experimental data availability for the target-end-
point, combined search (structural similarity & target endpoint 
data availability) or mechanistic similarity;
– tools to assess similarity between target and source compounds 
through structural similarity, mechanistic similarity, physico-
chemical and ADME similarity;
– tools to predict potential metabolism and metabolic products;
– QSAR predictors to predict target endpoint-related properties.
The big advantage of automation of source substance selection 
lies in the evaluation of many substances in a limited time. These 
approaches need to be used with care. They often simply identify 
“similar” analogues on the basis of chemical fingerprints, which 
may work for some endpoints but leaves the problems of activity 
cliffs if the fingerprints are not appropriate (Mellor et al., 2019). 
An example from skin sensitization is that a small change in 
structure can change a non-sensitizing molecule to one that can 
cause sensitization and vice versa. Still, already relatively simple 
nearest neighbor approaches were reported as quite successful in 
predicting this hazard (Luechtefeld et al., 2016b).
The addition of specific modules may make a difference from 
the perspective of regulatory acceptability. It is now clear that TK 
and metabolism are essential. When no data are available from in 
vivo studies, new models should be developed with the support of 
specific in vitro experiments. Given the complexity of RAx, au-
tomation only seems to make sense with respect to analogue se-
lection, but for regulatory acceptance also a comparison of other 
physicochemical and toxicological properties is required. 
The extent of familiarity with and uptake of automated tools as 
well as resources and guidance is mixed across the different agen-
cies. In some cases, there is a bias towards using QSAR approach-
es vs RAx, and the tools used vary between using the OECD Tool-
box or commissioning the development of new tools relying on 
other data streams. Harmonization and standardization of the ap-
proach as well as documenting the use of QSAR models as part of 
a workflow is desirable (Myatt et al., 2018). 
for reporting WoE28 , but guidance on how to combine different 
lines of evidence, how to best assign differential weights, and how 
to quantitatively combine those lines with the aim of minimizing 
residual uncertainty as well as how to manage discordant results is 
still missing.
Other important hurdles lie in the legal aspects of the right to re-
fer to proprietary data as is the case with the majority of study re-
ports. Even the public ECHA database has restrictions in the right 
to use, although a note explicitly allows download and use “to im-
prove the safe use of chemicals, enable innovation and help avoid 
the unnecessary testing of chemicals on animals”29. 
At the moment, there are two main available platforms: the 
OECD QSAR Toolbox and the EPA CompTox Chemicals Dash-
board. The OECD QSAR Toolbox16 is based on a variety of pub-
licly available databases for mammalian and environmental effects 
and includes the ECHA public database of registered substanc-
es. It is structured in a mechanistic way that enables the recon-
struction of the grouping process relevant for each endpoint. The 
EPA CompTox Chemicals Dashboard18 is compiled from sources 
including the EPA’s computational toxicology research data-
bases and other US public domain databases. The GenRA ap-
proach, which was developed with the aim of systematically and 
objectively evaluating the performance and quantifying the uncer-
tainties associated with read-across predictions, is included (Shah 
et al., 2016; Williams et al., 2017; Helman et al., 2018). The ide-
al future solution should exploit both platforms, and this is what 
the private tool REACHacross is proposing30 (Luechtefeld et al., 
2018b) through an advanced machine learning algorithm for iden-
tification of the most relevant chemical analogues ensuring reli-
able results, claiming to be just as accurate as other available ap-
proaches and animal testing (Luechtefeld et al., 2018a,b). 
There are also many other private tools that can be useful. Pat-
lewicz et al. (2017) performed a review of available in silico tools 
for grouping and inter alia compared them with a RAx workflow. 
The recent ICCVAM RAx working group publication also pro-
vides a description of freely available tools and insight into those 
used by regulatory agencies to support decision-making (Patle-
wicz et al., 2019). A fundamental prerequisite of any tool is the 
clear definition of the approach, with defined integration of QSAR 
assessment and the possibility to backtrack data history and ver-
sion of the tools, as well as a simple format output adhering to the 
OECD principles for QSAR validation (OECD, 2007).
A very interesting initiative is the VegaHub31 that developed spe-
cific tools, such as ToxRead, a software that builds up graphs con-
necting the target chemical and the structural alerts with the most 
similar compounds, to be used in combination with ToxWeight, 
which provides a WoE assessment joining QSAR and RAx, and 
ToxDelta focused on the molecular structure differences, namely 
the dissimilarity features (Gini et al., 2014; Golbamaki et al., 2017).
Another available platform and public tool is AMBIT232, which 
28 https://echa.europa.eu/documents/10162/17169198/wo_eu_uncertainty_background_en.docx/4f2b49ab-ade0-6ee3-e977-8abe00c21c23 
29 https://echa.europa.eu/-/data-on-15-000-chemicals-now-available-to-use 
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– QSAR model predictions,
– In vitro tests, with a focus on AOPs,
– TK/TD analysis.
This approach in its more elaborate form is relatively new and re-
quires specific expertise that at the moment is still limited. The 
roadmap for implementation and confident use of RAx requires 
actions in many areas with the collaboration of different stake-
holders.
A very important step is the generation of a template for RAx 
submission to the authorities with specific instructions on GRAP. 
In order to increase the confidence in the tool, the creation of exam-
ples that would be considered acceptable by regulators is key. Ex-
amples should include cases with compounds with high, low or no 
activity. A detailed analysis of uncertainty is a very important part 
of this. To this aim, workshops and symposia may contribute in the 
dissemination of the RAx principles.
Simultaneously, other actions should support raising awareness 
of regulators inside national authorities that RAx is a valid alterna-
tive, with the potential to increase confidence in the final outcome 
as it is based on a reasoned approach with a scientific justification 
of the mechanism. For this purpose, retrospective examples com-
paring both the traditional approach and the assessment performed 
with RAx should be prepared and presented.
On the other side, risk assessors from industry should also learn 
how to properly apply RAx. There is still much ignorance and ap-
prehension about using RAx in industry, and whilst much guidance 
and templates for reporting are available, real examples of success-
ful, i.e., accepted, RAx for data gap-filling would be beneficial. 
The industry needs to be reassured that the effort in preparing a rig-
orous RAx justification is largely repaid by regulatory acceptance 
without the need for additional in vivo studies.
Better harmonization of legislation is desirable. That should hap-
pen internationally, as it is unacceptable that a good RAx would 
be, for example, accepted in the EU and rejected in Japan or vice 
versa. It is not surprising that industry is reluctant to invest money 
into a strategy that is not accepted in other parts of the world. Un-
fortunately, the problem is not limited to crossing national borders, 
as sometimes important differences are present among different 
regulations enforced in the same region. Political action towards 
harmonization is necessary.
Another important aspect is education. RAx should be part of the 
program in university courses in toxicology and other related sub-
jects, in order to provide another useful tool for research and imple-
ment NAM approaches. 
RAx approaches are a dynamic and continually evolving devel-
opment. The area of mechanistic elucidation of toxicity pathways 
along with the increase of available information and computational 
tools is expanding dramatically, and each assessment should be up-
dated in parallel with the commitment to incorporate new evidence 
into existing RAx packages. These technologies offer the possibil-
ity of refinement of RAx justifications, which may lead to greater 
openness towards acceptance on the regulators’ side. International 
organizations such as the OECD have a leading role to play in sup-
porting the process definition.
4.3  Non-regulatory RAx 
RAx may also be useful outside the regulatory scope since it rep-
resents a valuable tool for research and early prediction. Develop-
ers of RAx systems should consider applicability in other scientific 
areas and possible users such as chemists, toxicologists or in edu-
cation, involving teachers and students.
RAx can find application in research and development con-
texts, e.g., at screening and prioritization level for the identifica-
tion of hazardous compounds to drive experimental testing or even 
to drive the synthesis of new molecules (“benign by design” con-
cept). These areas are also known as green toxicology, which is 
a sector of the green chemistry movement (Maertens et al., 2014; 
Maertens and Hartung, 2018) asking for less toxic products, safer 
processes, and less waste and exposure. In these contexts, group-
ing approaches should be more promising and useful than analogue 
approaches, with possible identification of trends that can be very 
useful in the selection of a new lead. Automated RAx tools can en-
hance the identification of unusual combinations of chemicals with 
the evaluation of the impact on toxicity generated by small chang-
es in the chemical structure. (NAM-based) RAx could also support 
green chemistry in the selection of substances suitable for replac-
ing substances of very high concern (SVHC). 
Specific use of RAx in academia can go beyond pure research 
as is the case for industry R&D. RAx should be part of teaching 
courses in toxicology and other disciplines, with practical sessions 
on case studies and emphasis on the importance of RAx as a nec-
essary professional qualification. RAx should be a valuable tool in 
mechanistic understanding as an ideal complement of pure com-
puter modelling systems. Academia should reason in a reverse 
way, i.e., frame their research questions and present their data in a 
machine-readable way with reports that contain all useful informa-
tion to enrich databases for RAx exploitation. Last but not least, the 
development and optimization of RAx tools represents a thriving 
research field for academic teams.
There are emerging applications also inside regulatory insti-
tutions. For example, two EPA Research Centers are engaged in 
the area of RAx. Within the National Center for Environmental 
Assessment (NCEA), RAx is routinely applied as part of the Su-
perfund program for provisional peer-reviewed toxicity values 
(PPRTVs). The workflow is documented in Wang et al. (2012). 
Beyond federal research centers, there are a number of opportuni-
ties under development to implement RAx in green chemistry ap-
proaches and screen chemicals during research and development 
by industry, e.g., the Leadscope models33 and the associated in sil-
ico protocols effort.
5  Conclusion / recommendations
RAx is potentially a major tool for risk assessment. The power of 
RAx lies in the possibility of combining data in a global analy-
sis, including:
– Data on analogues,
– Data on grouping, with identification of trends across a group,
33 http://www.leadscope.com/
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The fourth sector that is affected by RAx is contract research or-
ganizations (CROs) that usually perform new tests on behalf of in-
dustry and in many cases provide advice on test strategies. CROs 
should be aware of RAx possibilities and should implement NAMs 
in the list of their services. Widespread implementation will facili-
tate a decrease in the cost of in vitro tests, which is desirable to en-
courage their application to support RAx justification.
In addition, due to a general lack of strict guidance/rules for 
GRAP, chances of regulatory failure of a RAx submission are con-
siderably higher compared to, e.g., submitting the “traditional” 
standard information dataset as required by REACH. Against this 
background, many companies will prefer higher initial spending 
with guaranteed regulatory acceptance over an initially smaller in-
vestment, which might result in overall much higher costs when a 
RAx submission is rejected.
Last but not least, there is a need for the development of new 
tools for building RAx. This part is more complex. First of all, 
there should be an international agreement for data-sharing and 
free access to high-quality reports. Then there is the need for new 
databases with mechanistic information, combined with TK/TD 
data. In fact, at the moment, the request is to apply RAx simply to 
waive an extensive in vivo test, but considering the limitations of 
in vivo tests, the future trend is to develop a tool that increases pre-
dictivity and reliability by combining RAx approaches with multi-
ple NAMs.
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